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Abstract 
Acetaminophen (APAP) toxicity remains the leading cause of drug induced liver failure in the 
United States.  The current therapy for APAP toxicity is N-acetylcysteine (NAC).  NAC must be 
administered within eight hours of APAP overdose for maximum efficacy.  That, coupled with 
the fact that APAP toxicity may not be overtly evident, makes an alternative therapeutic 
intervention worth exploring.  Previous work by our laboratory has demonstrated that S-
adenosyl-L-methionine (SAMe) prevents APAP toxicity when given following APAP overdose 
in C57Bl/6 mice at a level comparable to NAC.  The focus of the current work was to examine 
the mechanistic aspects of this protection in the same mouse model.  Male C56Bl/6 mice were 
randomly allocated into Vehicle (water 15 mL/kg, ip), SAMe (1.25 mmol/kg, ip), APAP (250 
mg/kg, ip), and SAMe given one hour after APAP.  Mice were fasted the night before 
experiments and toxicity assessed using liver weight and plasma ALT.  Livers were collected 
from the mice at 2, 4, and 6 hours following APAP administration.  Our laboratory then 
examined levels of SAMe following APAP overdose alone and found that they were depressed 
by up to 60% and that SAMe given following APAP prevented this drop.  Additionally, we 
demonstrated protection of critical antioxidant pathways by SAMe following APAP overdose.  
This finding helps explain the previous observation by our laboratory that SAMe prevents an 
increase in oxidative stress markers following APAP toxicity.  We also demonstrated, for the 
first time, in our model that SAMe prevents oxidative damage in the mitochondria after APAP 
overdose.  However, SAMe was not able to prevent mitochondrial swelling in spite of other 
signs of mitochondrial protection.  Additionally, we also found that SAMe, a known substrate of 
the polyamine pathway, feeds into this pathway resulting in increased levels of the cytoprotective 
polyamines spermidine and spermine.  Finally, we verified prior findings of an ongoing 
xvii 
 
collaboration with Dr. Serrine Lau, University of Arizona, about 4-hydroxy-2-nonenal (4-HNE) 
protein adduction following APAP toxicity.  I also identified other potential mitochondrial 
targets of 4-HNE adduction.  My results demonstrate that SAMe is very effective as a therapeutic 
intervention for APAP toxicity in C57Bl/6 mice, an animal model that is known to metabolize 
APAP similarly to humans.  Our findings suggest a mechanism by which SAMe can prevent 
APAP toxicity. 
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Chapter I:  Introduction and Literature Review 
Acetaminophen 
Acetaminophen (APAP) is one of the most widely used analgesic, anti-pyretic over-the-counter 
(OTC) medications.  However, APAP is also the principal cause of drug induced acute liver 
failure (ALF) in the United States.  Between 2000 and 2007, there were an estimated 44,348 
cases of APAP intoxication resulting in emergency room visits annually (Manthripragada et al., 
2011).  The majority of those cases were intentional overdoses with APAP.  However, there is 
also danger to the casual consumer because APAP is present in many OTC medications raising 
the likelihood of accidental “double-dip” APAP overdose, particularly among children and the 
elderly.  APAP is present in at least 184 currently marketed OTC products, and extra labeling of 
APAP containing products has only recently been mandated by the FDA (Guggenheimer and 
Moore, 2011).  APAP is also present in at least 70 prescription medication combinations that 
patients may be taking concurrently with OTC products for pain management (2011). 
Despite the widespread use of APAP for over 50 years in the United States, its mechanism of 
action has only recently been understood.  APAP was assumed to act in a similar manner to non-
steroidal anti-inflammatory drugs (NSAIDs); however, although APAP displays good analgesic 
and anti-pyretic effects, it is not anti-inflammatory or anti-platelet (Anderson, 2008).  APAP 
does inhibit cyclooxygenase (COX) activity, although its mechanism is different from NSAIDs.   
Both COX-1 and 2 are sensitive to inhibition by APAP (Boutaud et al., 2002).  Unlike classical 
NSAID inhibition of COX, APAP does not appear to act at the active site of the enzyme.  Rather, 
APAP reduces the enzyme to an inactive form (Lucas et al., 2005).  This mechanism is supported 
by the work of Boutaud and Lucas (2002 and 2005), who found that addition of peroxides 
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reduced the ability of APAP to inhibit COX enzymes, particularly COX-2.  APAP also increases 
COX-2 expression in rat cerebral endothelial cells, consistent with its ability to inhibit central 
pain (Kis et al., 2005b).   
A third COX isozyme, COX-3 is found in canines (Chandrasekharan et al., 2002) and mice 
(Ayoub et al., 2006).  COX-3 is a central nervous system splice variant of COX-1 that retains the 
first intron.  Although COX-3 is inhibited by APAP, the human form of COX-3 is a non-
functional protein because of a frame shift brought about by a different length of intron 1 (Kis et 
al., 2005a).  For this reason, COX-3 has been discounted as a major cause of APAP induced 
analgesia in humans. 
Another possible mechanism for APAP analgesia and anti-pyresia is its conversion to an N-
acylphenolamine (AM404) that acts centrally on the cannabinoid pathway (Hogestatt et al., 
2005).  Following deacetylation of APAP in the liver, p-aminophenol travels to the brain where 
it is conjugated by fatty acid amide hydrolase (FAAH) to arachidonic acid forming AM404.  
AM404 then interacts with the capsaicin TRPV1 receptor to mediate reduction of pain and fever.  
Of note is the finding that the liver did not also produce AM404 in measurable quantities despite 
a large concentration of FAAH.  The authors postulate that AM404 is rapidly metabolized in the 
liver to another compound whereas it is maintained for a longer period in the brain allowing for 
it to exert its function.  In addition to acting at TRPV1, AM404 inhibits both COX-1 and COX-2 
which may be another method of inhibition of these enzymes caused by APAP. 
Lending credence to the cannabinoid pathway’s importance in APAP pain relief is that 
antagonism of CB1 receptors prevents APAP associated analgesia in Wistar rats (Ottani et al., 
2006).  AM404 also activates the CB1 receptor in addition to the TRPV1 receptor which in turn 
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activates analgesic serotonergic receptors in the spinal column producing analgesia (Mallet et al., 
2008).  Additionally, AM404 induces significant, dose dependent hypothermia in Sprague-
Dawley rats consistent with the anti-pyretic properties of APAP (Rawls et al., 2006).  TRPV1 
was again noted as the likely receptor for mediating AM404’s induction of hypothermia.  
Another tangential, but confirmatory, piece of evidence in favor of the cannabinoid pathway’s 
involvement in APAPs mechanism of action is the observation that APAP possesses dose-
dependent anxiolytic effects in mice thought to be mediated predominantly by CB1 receptors 
(Umathe et al., 2009). 
Although the exact mechanism of action for APAP remains to be discovered, its metabolism is 
well characterized.  APAP is principally metabolized in 1 of 3 manners:  glucuronidation, 
sulfation, or oxidation by cytochrome P450s (CYPs) to the reactive metabolite N-acetyl-p-
benzoquinoneimine (NAPQI).  At gastric pH APAP is neutrally charged and, therefore, 
predominantly absorbed in the small intestine (Heading et al., 1973).  As a result, the rate of 
gastric emptying is directly proportional to APAP absorption in the body and subsequent 
excretion of metabolites.  APAP undergoes some Phase II metabolism intestinally prior to 
entering the liver.  Glucuronidation is rapidly saturated as APAP levels increase leaving sulfation 
as the predominant form of metabolism in the intestine (Goon and Klaassen, 1990). 
Following absorption, APAP is transported via the portal circulation to the liver before entering 
the systemic circulation.  Metabolism occurs primarily in the liver. Urinary metabolite analysis 
indicates that approximately 60% of urinary APAP is excreted as a glucuronic acid conjugate, 
30% conjugated to sulfate, 8% as either cysteine or mercapturate conjugates, and the remaining 
4% as unchanged APAP (Cummings et al., 1967; Levy and Yamada, 1971; Prescott, 1980).  
Additionally, APAP-glucuronide is excreted in the bile to a greater extent than either APAP-
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sulfate or APAP-glutathione (Hjelle and Klaassen, 1984).  Taken together, these studies indicate 
that the vast majority of a therapeutic dose of APAP is safely metabolized by glucuronidation or 
sulfation, leaving approximately 5-10% of the dose for oxidation via P450 isozymes (Figure 1).   
Gender differences play a minor role in APAP metabolism as women exhibit decreased 
clearance of APAP compared to men, most likely as a consequence of increased glucuronidation 
of APAP in men (Miners et al., 1983).  Pregnant women and women on oral contraceptives clear 
APAP more rapidly than men because of increased rates of APAP glucuronidation and 
glutathione conjugation (Miners et al., 1986).  Once adulthood is reached, no significant 
differences are observed in glucuronidation or sulfation based on age (Herd et al., 1991).  APAP 
metabolism is dramatically different in neonates and children under 9 years of age when 
compared with adolescents and adults.  In urinary metabolites, sulfation of APAP predominates 
over glucuronidation up to 9 years of age (Levy et al., 1975; Miller et al., 1976).  The difference 
in metabolism of APAP in the young is easily explained by the delayed expression of 
glucuronidation enzymes at early ages (de Wildt et al., 1999). 
The purpose of both glucuronidation and sulfation is to make APAP more polar to aid in 
excretion.  Glucuronidation relies on the cofactor uridine diphosphate-glucuronic acid (UDPGA) 
and UDP-glucuronosyltransferases (UGTs) to attach a glucuronic acid to the para-hydroxyl 
group of APAP (Parkinson, 2001).  Human glucuronidation of APAP is mediated by UGT1A1, 
1A6, 1A9, and 2B15 (Court et al., 2001; Mutlib et al., 2006).  Isoforms 1A9 and 2B15 are 
thought to have the highest capacity, although with lower affinity for APAP than the other 
relevant isotypes.  Additionally, 1A6 displays a marked decrease in activity with increasing 
concentrations of APAP, indicating possible substrate inhibition.  The major limiting factor in 
glucuronidation of APAP appears to be the synthesis of the cofactor UDPGA, which is depleted 
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by APAP in a dose dependent manner (Price and Jollow, 1984).  APAP glucuronidation occurs 
at highest capacity in the periportal region of the liver away from the primary centrilobular site 
of necrosis observed during liver toxicity (Mitchell et al., 1989). 
Sulfation also serves to increase the polarity of APAP and aid in excretion.  Sulfotransferases 
(SULTs) catalyze sulfation reactions with the cofactor 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) acting as the sulfate donor (Parkinson, 2001).  SULTs are generally thought to have 
higher affinity for their substrates than UGTs, but they operate at a slower rate than 
corresponding UGTs.  SULT1A1 and 1A3 are well characterized SULTs that are responsible for 
the bulk of APAP sulfation in vivo (Reiter and Weinshilboum, 1982).  Several polymorphic 
variants of SULT1A1 have been examined with widely varying rates of metabolism.  The rate of 
reaction for SULT1A1*2 is greatly reduced compared to the *1 and *3 variants and could 
potentially be of importance for inter-individual differences in APAP sulfation (Nagar et al., 
2006). 
Toxicity caused by APAP is mediated by the toxic metabolite NAPQI, which causes severe, 
devastating centrilobular necrosis (Lesna et al., 1976).  Evidence has existed since the early 
1980s that NAPQI was the toxic metabolite of APAP and was formed through the two electron 
oxidation of APAP to a reactive quinone (Dahlin et al., 1984; Potter and Hinson, 1987).  NAPQI 
has a 4-aminophenoxyl radical intermediate, which could contribute to the oxidative stress 
observed with APAP toxicity; however, a study by Fisher and others (1985) determined that the 
intermediate did not react with oxygen to form superoxide.      
The formation of NAPQI is catalyzed by the CYP superfamily of enzymes.  The four major 
CYPs in human APAP metabolism are CYP2E1, 3A4, 1A2, and 2D6 (Laine et al., 2009).  In 
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humans, CYP2E1 is the major isozyme responsible for metabolism of APAP in vivo (Manyike et 
al., 2000).  CYP2E1 is highly concentrated in the centrilobular regions of the liver, 
corresponding with the site of APAP induced toxicity (Anundi et al., 1993).  Inhibition of 
CYP3A4, 2E1, and 1A2 with a cocktail of ketoconazole, isoniazid, and caffeine effectively 
prevents APAP toxicity in rats (Walubo et al., 2004).  However, CYP inhibitors have not gained 
favor for use in humans to prevent APAP toxicity because of their significant side effect profiles.  
CYP2D6 metabolism of APAP is interesting because of the variable activity of this particular 
isozyme in humans.  Persons possessing a faster metabolizing single nucleotide polymorphism of 
CYP2D6 may be more likely to experience APAP toxicity at lower doses (Dong et al., 2000).  
At therapeutic doses of APAP, NAPQI is rapidly adducted at the 3’ position by GSH and 
excreted primarily as a biliary metabolite (Hinson et al., 1982).  The glutathione adduct of APAP 
is further metabolized to a mercapturic acid conjugate, also commonly found following APAP 
administration.  APAP-GSH conjugation can proceed in either an enzymatic or non-enzymatic 
pathway.  The enzymatic reactions are catalyzed by the glutathione S-transferase enzymes 
(GST).  These enzymes are heavily localized in the centrilobular region of liver lobules, although 
they are found throughout the lobule (Redick et al., 1982).  Additionally, GSTs in the 
centrilobular region express much higher activity as the concentration of substrate increases, 
which would be crucial in the APAP detoxification pathway (Kera et al., 1987).  A seminal paper 
by Coles and others in 1988 found that the rate of spontaneous vs. enzymatically catalyzed 
NAPQI conjugation with GSH depended on levels of NAPQI (Coles et al., 1988).  The 
spontaneous reaction of NAPQI with GSH produced a 2:1:1 ratio of APAP-SG, APAP, and 
GSSG respectively.  Additionally, the spontaneous reaction rate increased dramatically at higher 
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levels of NAPQI.  The enzymatic reaction was catalyzed mainly by GST 2-2, 3-3, and 7-7 and 
was much more prevalent at lower levels of NAPQI.   
At therapeutic doses, GSH is excellent at detoxifying NAPQI before cellular damage occurs.  
However, GSH becomes depleted with APAP overdose and NAPQI rapidly adducts hepatic 
proteins causing cell damage.  The most common type of protein adduction occurs with free 
cysteine sulfhydryl groups in proteins (Hoffmann et al., 1985).  However, there is also evidence 
that cysteine alone cannot account for all of the adduction observed with NAPQI (Streeter et al., 
1984).  Streeter and others observed that bovine serum albumin (BSA), with one free sulfhydryl 
group, demonstrated excess adduction by NAPQI beyond that which could be explained by 
cysteine adduction alone.  Recent work suggests that the alternate sites of adduction are on lysine 
and histidine residues (Zhou et al., 1996).  An alternative ipso adduct, formed by a 1, 2 addition 
rather than a 1, 4 addition, exists between cysteine and NAPQI (Chen et al., 1999).   This adduct 
seems to occur less frequently than the traditional 1, 4-Michael addition of NAPQI to cysteine; 
however, it has a longer half-life and reverses with GSH.  The reversible nature of the adduct is 
of interest because it could allow the normally short-lived NAPQI to be transported to more 
distant portions of the cells. 
Site specificity for NAPQI protein adducts is important to the observed toxicity.  The APAP 
regioisomer 3’-hydroxyacetanilide (AMAP) does not manifest the toxicity observed with APAP 
even though it is also metabolized to a reactive metabolite.  APAP preferentially binds 
mitochondrial proteins whereas AMAP binds primarily microsomal proteins (Nelson et al., 
1991).  Additionally, APAP causes more oxidation within cells as evidenced by the conversion 
of xanthine dehydrogenase to xanthine oxidase.  Indeed, Nelson’s work demonstrates that 
AMAP can only cause toxicity with depletion of mitochondrial GSH.  The issue of binding 
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specificity is further reinforced by the fact that APAP and AMAP bind plasma membrane 
proteins equally (Tirmenstein and Nelson, 1989).  Also, only APAP selectively depletes 
mitochondrial GSH even though both AMAP and APAP deplete total cellular GSH.  APAP also 
depletes ATP and the total pool of nucleotides, while AMAP does not (Tirmenstein and Nelson, 
1990).    All of these observations indicate that the mitochondria are a target of NAPQI and that 
mitochondrial dysfunction is a hallmark of APAP toxicity. 
One of the early events in the progression of APAP toxicity is cellular ATP depletion brought 
about by mitochondrial damage.  NAPQI is capable of inhibiting both Complexes I and II in the 
mitochondrial respiratory chain, disrupting the proton gradient necessary for ATP production 
(Burcham and Harman, 1991).  Also, NAPQI directly adducts ATP synthase inhibiting 
production of ATP (Qiu et al., 1998).  ATP depletion is critical to the ultimate toxicity of APAP 
because it interrupts the normal mitochondrial induced death pathways in hepatocytes.   
A key event subsequent to NAPQI formation in APAP toxicity is the production of both reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). GSH depletion in mouse models is 
rapid, occurring within 20 minutes of administration to mice (Jaeschke, 1990).  Like other 
aspects of APAP toxicity, GSH depletion precedes ROS generation. In fact, mitochondrial 
damage can lead to the production of ROS. A common indicator of mitochondrial ROS 
generation is the formation of GSSG, and this compound is found in the mitochondria within 15 
minutes of APAP administration (Knight et al., 2001).  With the loss of mitochondrial GSH, 
superoxide produced by the damaged mitochondria is free to react with nitric oxide forming 
peroxynitrite.  
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One area of controversy is the source of nitric oxide in the hepatocytes. Some studies involving 
the inhibition of inducible nitric oxide synthase (iNOS) demonstrate a greatly decreased toxicity 
indicating the role the protein plays in acetaminophen toxicity (Kamanaka et al., 2003).  Recent 
work appears to contradict prior studies by showing that iNOS is not the primary source of nitric 
oxide for the formation of peroxynitrite because inhibiting its activity does not alter toxicity or 
protein nitration (Burke et al., 2010). The same study demonstrated that nonspecific nitric oxide 
synthase (NOS) inhibition did decrease toxicity suggesting that basal nitric oxide may be 
sufficient to explain the generation of peroxynitrite associated with APAP toxicity. 
 The production of peroxynitrite leads to protein nitration and is a precursor to mitochondrial 
permeability transition (MPT). Protein nitration is predominantly localized to the centrilobular 
region of the liver consistent with acetaminophen toxicity (Knight et al., 2001).  Furthermore, 
scavenging peroxynitrite with GSH administered 1.5 hours after APAP not only aided survival of 
mice injected with a toxic dose of APAP, but it also aided cellular regeneration (Bajt et al., 
2003).   
Peroxynitrite also directly induces mitochondrial damage as indicated by reduction of intact 
mitochondrial DNA and nitrotyrosine protein adducts localized to the mitochondria following 
APAP toxicity (Cover et al., 2005a).  Mitochondria have a well characterized defense 
mechanism consisting of several antioxidant enzymes including: catalase, glutathione peroxidase 
(GPx), glutathione reductase, and manganese superoxide dismutase (SOD) (Figure 2).  APAP 
toxicity decreases the function of all of these antioxidant enzymes (Olaleye and Rocha, 2008; 
Wu et al., 2009). Without a mechanism to detoxify superoxide, excess peroxynitrite formation 
can damage the cell leading to the opening of the MPT pore and subsequent necrosis observed 
with APAP toxicity. 
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MPT is characterized by loss of mitochondrial membrane potential and permeabilization of the 
membrane to solutes greater than 1.5 kDa (Aniya and Imaizumi, 2011).  Cyclosporin A, a known 
inhibitor of MPT, reduces hepatotoxicity associated with APAP overdose in mice (Masubuchi et 
al., 2005).  However, even when cyclophilin D, a key component of the MPT pore, is knocked 
out, elevated levels of peroxynitrite produced with high doses of APAP are sufficient to induce 
necrosis in hepatocytes indicating, again, the complexity of APAP toxicity (Loguidice and 
Boelsterli, 2011).  Bax is also known to be a component of the MPT pore.  Bajt and others 
(2008) found that Bax knockout mice were still susceptible to APAP toxicity when given 300 
mg/kg APAP because oxidative stress eventually overwhelms mitochondrial function.  These 
findings coupled with the cyclophilin D knockout experiments point to a much more complex 
picture of APAP toxicity where a number of factors can cause cellular necrosis; however, recent 
work has also demonstrated potential targets for treatment to halt the progression of the MPT 
component of toxicity following APAP overdose.   
Recent efforts to link the massive increase in oxidative stress and MPT in APAP toxicity have 
focused on C-Jun N-Terminal Kinase (JNK).  JNK inhibition protects against APAP toxicity 
even when the inhibitor is administered up to six hours following APAP (Gunawan et al., 2006).  
Following activation, JNK facilitates Bax translocation to and permeabilization of the 
mitochondrial membrane.  JNK activation is further linked to mitochondrial dysfunction by the 
observation that AMAP, which does not decrease mitochondrial GSH, was unable to activate 
JNK and induce the permeability transition seen with APAP (Hanawa et al., 2008). 
Inhibition of JNK by the inhibitor leflunomide (SP600125) reduces mitochondrial cytochrome c 
release following APAP toxicity (Saito et al., 2010).  Another study using the same inhibitor 
demonstrated prevention of nitrotyrosine formation (Latchoumycandane et al., 2007).  
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Leflunomide also protected ATP production in hepatocytes by inhibiting JNK activation.  
Knock-out of apoptosis signal-regulating kinase 1 (ASK1), which regulates the JNK pathway, 
imparted greater long-term survival to the mice compared with controls, even though indicators 
of toxicity were initially similar (Nakagawa et al., 2008).  All signs point to JNK playing an 
important role in APAP toxicity. 
APAP hepatotoxicity induces DNA fragmentation which may involve JNK activation.  APAP 
overdose resulted in DNA fragmentation that occurred within 2 hours after treatment (Ray et al., 
1990).  Recent work demonstrated that the formation of the permeability pore lead to release of 
both apoptosis inducing factor (AIF) and endonuclease G that are thought to be responsible for a 
portion of the observed DNA fragmentation (Bajt et al., 2006).   
Finally, another molecular marker of APAP induced oxidative stress is 4-hydroxy-2-nonenal (4-
HNE).  This compound is an electrophilic breakdown product of poly-unsaturated fatty acids in 
cell membranes experiencing oxidative stress (Roede and Jones, 2010).  4-HNE is highly 
electrophilic and can subsequently bind cellular proteins if not appropriately detoxified.  It is 
known to bind cysteine, histidine, and lysine similar to NAPQI resulting in cellular damage.  
However, 4-HNE is efficiently metabolized by the cell when produced at normal physiological 
conditions.  In hepatocytes, alcohol dehydrogenase, aldehyde dehydrogenase and GST are 
responsible for the majority of 4-HNE detoxification (Hartley et al., 1995).  Although 4-HNE is 
clearly produced in response to APAP overdose, it is not clear what role it may have in APAP 
toxicity. 
Early work postulated that lipid peroxidation and subsequent formation of 4-HNE played a 
significant role in APAP toxicity (Fairhurst et al., 1982).  Certainly given the role of GST in 
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detoxification of 4-HNE it is plausible that the loss of GSH associated with GST activity could 
contribute to APAP toxicity even in the absence of a direct role for 4-HNE.  However, a recent 
study by Knight and others found that when lipid peroxidation was inhibited, APAP toxicity was 
not affected (Knight et al., 2003).  While this investigation casts doubt on 4-HNE as a causative 
agent in APAP toxicity, it does not entirely preclude a role for 4-HNE.  In fact, mice with 
metabolic syndrome have a significant increase in toxicity when they received doses of APAP 
equal to controls (Kon et al., 2010).  The authors theorize this is due to increased oxidative stress 
in the metabolic syndrome mice.  The increasing incidence of metabolic syndrome in the United 
States could increase APAP toxicity.    
There is a well-established treatment for APAP overdose, N-acetyl-L-cysteine (NAC).  This 
antidote functions by providing cysteine to the hepatocytes since this is the rate limiting amino 
acid in GSH synthesis (Lauterburg et al., 1983).  Lauterburg and others found that NAC 
replenishes cellular GSH depleted by APAP toxicity, without adducting APAP directly.   
There are currently two NAC protocols in use for the treatment of APAP overdose.  The first is a 
72 hour oral treatment regimen.  The patient is given a loading dose of NAC (140 mg/kg) and 
then subsequent doses of 70 mg/kg every 4 hours out to 72 hours (2012).  However, this is often 
unpalatable to the patient due to the unpleasant odor of NAC.  Therefore, an intravenous (IV) 
dosing schedule was developed that takes 21 hours.  A loading dose of 150 mg/kg of NAC is 
infused over 1 hour followed by 50 mg/kg infused over 4 hours and finally 100 mg/kg infused 
over 16 hours until completion.  Although effective as a therapy, NAC has some drawbacks.  As 
mentioned above, it is not the most palatable of drugs.  Additionally, there is a time sensitive 
component to NAC administration.  For maximum efficacy, the oral dose must be administered 
within 8-10 hours of APAP ingestion, and the IV regimen must be used when the patient is over 
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10 hours past APAP ingestion (Kanter, 2006).  Therapy that could go beyond this time limitation 
would be beneficial to patients who delay in seeking treatment. 
 
Figure 1.  APAP metabolic pathway.  The vast majority of a typical APAP dose is metabolized 
through glucuronidation (60%) and sulfation (30%).  The remaining 5-10% of the dose is 
oxidized by CYP2E1, 3A4, 1A2, and 2D6 to the reactive metabolite NAPQI.  Provided GSH 
stores are sufficient, GSH detoxifies the NAPQI and it is excreted as either a cysteine or 
mercapturic acid conjugate.  However, lack of GSH such as during a toxic dose of APAP results 
in protein adduction and hepatotoxicity. 
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Figure 2.  Cellular antioxidant pathway. Superoxide (O2
.
)
 
is converted to hydrogen peroxide 
H2O2  by superoxide dismutase (SOD) and then to water by either catalase or glutathione 
peroxidase (GPx).  Glutathione disulfide or oxidized glutathione (GSSG) is converted to reduced 
glutathione (GSH) through the action of glutathione reductase (GSSG reductase).  Glucose 6-
phosphate dehydrogenase (G6PD) regenerates NADPH which is a necessary cofactor for GSSG 
reductase.   
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S-Adenosyl-L-Methionine 
S-Adenosyl-L-methionine (SAMe) was discovered in the 1950s by Giulio Cantoni while 
conducting research at Case Western University (Kresge et al., 2005).  He was the first person to 
discover that SAMe was a major cofactor in biological methylation reactions.  However, SAMe 
also has many other roles within the cell.  SAMe is second only to ATP in the number of 
reactions for which it acts as a cofactor (Lu, 2000).  In fact, 6-8 g of SAMe is produced by the 
body every day, suggesting that this compound plays vital roles in cellular physiology.   
SAMe is the principal biological methyl donor in mammals (Finkelstein, 1990).  Its rate of 
formation is governed by the methionine cycle (Figure 3).  SAMe synthesis involves the 
activation of methionine by combining it with ATP (Mudd, 1963).  This reaction is catalyzed by 
one of three variants of the enzyme methionine adenosyltransferase (MAT).  MAT I and III are 
expressed in the adult liver.  The difference between the isozymes is that MAT I is a tetramer 
and MAT III is a dimer expressed from the same gene (Kotb et al., 1997).  Both MAT I and 
MAT III are constitutively expressed in the liver, correlating with this organ being the primary 
site of methionine metabolism in the body.   
Unlike MAT I/III, MAT II is expressed in every other location in the body, with only a very 
small amount being found in the liver.  MAT II also consists of a different catalytic subunit from 
MAT I/III, and a Beta subunit (Kotb et al., 1997).  Further research found that the Beta subunit 
serves a regulatory function for the extrahepatic MAT II (De La Rosa et al., 1995).  Comparisons 
of all the isozymes indicate that MAT II has the highest affinity for its substrates followed by 
MAT I and then MAT III (Sullivan and Hoffman, 1983). 
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MAT is important to my thesis work because of its differential expression in response to cellular 
stresses.  For instance, MAT II expression is upregulated in liver cancer and is thought to provide 
the tumor cells with a survival advantage (Cai et al., 1998).  While tumors represent a distant 
connection at best with APAP toxicity, strong evidence documents the critical role of SAMe 
produced by the MAT II isozyme, in liver growth.   
In addition, Huang and others found that both MAT1A and MAT2A genes were upregulated 
following partial hepatectomy in rats (Huang et al., 1998).  MAT1A codes for the subunits found 
in MAT I/III and MAT2A for MAT II.  However, MAT2A mRNA remained significantly 
elevated out to 3 days post-surgery while at the same time point MAT1A fell below control 
levels.  Another study used hepatocyte growth factor to induce proliferation in the H35 hepatoma 
cell line.  Huang and coworkers (1998) found that when MAT2A expression was decreased by 
the use of antisense nucleotides growth of the hepatoma cell line was decreased significantly.  
Multiple studies indicate an important role played by SAMe following liver damage and that 
MAT II is the predominant isozyme involved in providing this essential factor.  MAT II 
expression is closely tied to proliferation of the hepatocytes and that its promoters are linked 
with cell cycle progression (Rodriguez et al., 2007).   
Following synthesis, SAMe is a substrate for three pathways.  SAMe can donate a methyl group 
to a variety of cellular substrates becoming S-adenosylhomocysteine (SAH) in the 
transmethylation portion of the methionine pathway (Finkelstein, 1990).  Following de-
adenylation, SAH can become homocysteine, which can then provide a cellular source of 
cysteine to replenish GSH stores (Figure 3).  SAMe serving as a source of cysteine represents the 
trans-sulfuration component of SAMe activity.  Finally, SAMe can be decarboxylated and serve 
as a propylamine donor for polyamine synthesis (Finkelstein, 1990). 
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The importance of the transmethylation pathways within cells are underscored by the fact that all 
of the five classes of methylase proteins known to exist evolved independently from one another 
(Schubert et al., 2003).  This evolutionary diversity is represented in the wide range of 
intracellular targets for the methylases.  Common targets for the methylases are DNA, proteins, 
and phospholipids at carbon, sulfur, nitrogen, and oxygen.  Transmethylation reactions are 
governed by the ratio of SAMe:SAH.  SAH elevations significantly reduce the methylation of 
histones, DNA, and phosphatidyl choline (Hoffman et al., 1980).  Following donation of a 
methyl group, SAMe can be recycled back into methionine.  S-adenosylhomocysteine hydrolase 
removes the adenosine from SAH to form homocysteine (Brosnan and Brosnan, 2006).  Then, 
methionine synthase or betaine:homocysteine methyltransferase use tetrahydrofolic acid or 
betaine respectively to resynthesize methionine.  The trans-sulfuration pathway plays a critical 
role in replenishment of cellular GSH.   Almost half of the daily dietary methionine is converted 
to SAMe which serves as a substrate for trans-sulfuration (Lu, 1999).  The enzyme cystathionine 
-synthase (CBS) plays a prominent role determining whether homocysteine gets recycled to 
methionine or ends up as cysteine to replenish cellular GSH or taurine.  CBS catalyzes the 
irreversible conversion of homocysteine to cystathionine through the addition of serine (Lu, 
1999).  In the presence of adequate cellular cysteine, CBS activity is greatly diminished leading 
to more creation of methionine and SAMe within the hepatocyte (Finkelstein et al., 1986).  
Cystathionine is then converted to cysteine through deamination by cystathionine -lyase (CGL) 
where it can become GSH, taurine, or be incorporated into protein (Brosnan and Brosnan, 2006).   
The final pathway for SAMe that has relevance to my thesis research is the role of SAMe in the 
synthesis of polyamines (Figure 4).  The first step in polyamine pathway is the de novo synthesis 
of putrescine (Put) by ornithine decarboxylase (ODC) (Coleman et al., 2004).  There are other 
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sources of ornithine in organisms, but the relevant pathway for humans goes through ODC.  
Arginase was assumed to provide the necessary ornithine for ODC to function, but recent work 
by Deignan and others casts doubt on this supposition.  They found that levels of polyamines in 
the liver were generally unperturbed in arginase knockout mice (Deignan et al., 2007).  
ODC activity also increases during liver regeneration indicating the critical role of polyamines in 
liver growth and development following injury (Holtta and Janne, 1972).  Because it acts as one 
of the two rate limiting steps in polyamine synthesis, ODC is tightly regulated by levels of 
polyamines.  Antizyme (AZ) inhibits translation of ODC reducing expression when spermidine 
(Spd) is high within the cell (Kurian et al., 2011).   
The next two steps in polyamine synthesis require decarboxylated SAMe (dcSAMe) produced by 
S-adenosylmethionine decarboxylase (SAMDC).  dcSAMe serves as a propylamine donor for the 
synthesis of Spd and spermine (Spm) from Put (Urdiales et al., 2001).  Inhibition of S-
adenosylmethionine decarboxylase decreases hepatocyte regeneration following partial 
hepatectomy in rats (Wiegand and Pegg, 1978).  S-adenosylmethionine decarboxylase is 
stabilized by lack of spermidine in cells (Shirahata and Pegg, 1985).  Additionally, high Put and 
low Spd and Spm are all known to increase the activity of S-Adenosylmethionine decarboxylase.  
Inhibition of the enzyme greatly increases cellular Put levels indicating that S-
adenosylmethionine decarboxylase, like ODC, is a rate limiting step in the synthesis of 
polyamines (Stjernborg et al., 1993). 
When an adequate amount of dcSAMe and Put are available, synthesis of the polyamines Spd 
and Spm may proceed.  Spd and Spm are synthesized by the sequential addition of propylamine 
groups from dcSAMe by spermidine synthase and spermine synthase respectively (Urdiales et 
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al., 2001).  The entire process of polyamine synthesis can then be reversed through two separate 
enzymes.  First, Spd or Spm are acetylated by spermidine/spermine N
1
-acetyltransferase (SSAT) 
(Casero et al., 1990).  Then, Spd and Spm are oxidized back to Put and Spd respectively by 
polyamine oxidase (PAO), allowing a quick response to cellular needs (Vujcic et al., 2003).  The 
fact that SAMe can participate in polyamine synthesis represents a potential unique advantage 
over the current treatment for APAP toxicity, NAC.  Spm and Spd have many growth promoting 
and mitochondrial protective properties (Park, 2006).  Unlike SAMe, there is no clear path for 
NAC to create polyamines meaning that SAMe may have a multifaceted protective mechanism 
against APAP toxicity. 
Polyamines have a variety of roles within cells, but perhaps the most pertinent to the current 
discussion is their ability to induce hepatocyte growth and activate stress response genes.  
Polyamine gene expression can be driven by ROS generation within the cell (Rhee et al., 2007).  
Additionally, the polyamine Spd is absolutely necessary for the synthesis of active eukaryotic 
translation initiation factor 5A (EIF5A).  This regulatory factor requires the modified amino acid 
hypusine for it to be active and is critical in eukaryotic cellular growth and development (Park, 
2006).  Spd donates the crucial butyl amine group necessary to form hypusine on EIF5A.  Recent 
work further supports the role of Spd in eukaryotic translation.  A comparison of Spd and Spm 
depletion and their effect on EIF5A synthesis, revealed that without Spd, cell growth was 
arrested (Hyvonen et al., 2007).   
Although the effects of APAP toxicity on polyamine levels have not been studied, other 
toxicants have been found to alter polyamine levels.  Carbon tetrachloride leads to an increase in 
Put within 24 hours of administration followed by an increase in Spd by 48 hours in the mouse 
liver (Poso and Pegg, 1982).  Additionally, administering Put following D-galactosamine in rats 
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was able to prevent the decrease of Spd and Spm common with toxicity (Daikuhara et al., 1979).  
To our knowledge, no studies have previously looked at the effect of administering SAMe 
following APAP toxicity on polyamine levels within the liver.    
In addition to being increased long-term in response to a variety of toxicants, polyamines also 
have mitochondrial protective traits.  Particularly, the polyamine Spm appears to play a critical 
role in mitochondrial health.  Spm decreases cytochrome c release in thymocytes exposed to 
dexamethasone (Hegardt et al., 2003).  Although the thymocytes are undergoing apoptosis 
instead of necrosis in the experiment, APAP clearly increases release of cytochrome c early in its 
toxicity.  Additionally, Spm inhibits mitochondrial swelling analogous to APAP toxicity while 
protecting oxidative phosphorylation within the mitochondria (Rigobello et al., 1993).  Indeed, 
Spm has quite an affinity for de-energized mitochondria indicating its protective role against 
MPT (Dalla Via et al., 1998).  An additional protective role for Spm is its ability to scavenge free 
radicals such as those known to cause damage with APAP toxicity (Sava et al., 2006). 
Because of the wide diversity of SAMe functions within the human body, it has been thoroughly 
explored for a variety of medical conditions.  For instance, SAMe may reduce pain in those 
suffering from osteoarthritis, but the data is mixed (Rutjes et al., 2009).  Also, the role of SAMe 
in the synthesis of neurotransmitters led to its investigation for treatment of depression.  SAMe 
appears to be beneficial when it is used to treat major depressive disorder (Nelson, 2010).  
Additionally, there appears to be a symptomatic and quality of life improvement for fibromyalgia 
patients treated with SAMe (Jacobsen et al., 1991).  Finally, there is mixed to slightly positive 
evidence according to the Cochrane Review, that SAMe aids people suffering from alcohol 
induced cirrhosis of the liver (Rambaldi and Gluud, 2006).  Cirrhosis disrupts normal methionine 
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metabolism and supplementing with SAMe provides activated methionine normally not 
generated by the cirrhotic liver.   
Although SAMe holds promise in some of these disease states, the focus of my work is on its 
ability to protect against APAP induced toxicity and potentially aid in regeneration of the liver 
following APAP overdose.  APAP toxicity significantly depresses ATP levels within cells.  A 
study by Shan and others concluded that loss of ATP significantly decreases the production of 
GSH in hepatocytes (Shan et al., 1989).  SAMe given to people with liver disease is known to 
increase levels of GSH restoring protective antioxidant activity to the cell (Vendemiale et al., 
1989).  Also, in spite of different toxicity mechanisms, ethanol abuse also depletes cellular and 
mitochondrial GSH.   
Several studies report the ability of SAMe to protect mitochondrial GSH depletion brought about 
by ethanol use (Fernandez-Checa et al., 2002; Garcia-Ruiz et al., 1995).  Mitochondria are the 
predominant source of oxidative stress in APAP toxicity, and the maintenance of GSH would aid 
in absorbing the increase in ROS and RNS caused by APAP.  SAMe given before 
ischemia/reperfusion injury to the liver improves not only cellular and mitochondrial SAMe, but 
also the ratio of GSH:GSSG (Kaneshiro et al., 1998).  SAMe obviously protects against 
mitochondrial GSH depletion and studies suggest that it is also actively transported into 
mitochondria. 
Recent studies have characterized, at least in humans and yeast, a mitochondrial SAMe 
transporter.  The transporter, SAMC, is found in most major tissues with the liver containing a 
fairly high expression level (Agrimi et al., 2004).  Additionally, SAMe is able to protect 
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oxidative phosphorylation while also protecting the mitochondrial genome in models of ethanol 
toxicity in the liver (Bailey et al., 2006). 
These properties of SAMe suggest it would be useful to prevent and treat APAP toxicity 
following overdose.  Our laboratory and others have proven the efficacy of SAMe in preventing 
APAP toxicity when given before and after APAP (Bray et al., 1992; Song et al., 2004; 
Stramentinoli et al., 1979; Terneus et al., 2008).  However, given the myriad of roles SAMe has 
within the cell, its true mechanism of action is most likely multifaceted and not completely 
understood.  Thus, the rationale for my thesis research was to better characterize how SAMe 
provides protection against APAP overdose and to determine its therapeutic potential as a new or 
concomitant treatment with NAC for APAP toxicity.   
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Figure 3.  SAMe and the methionine cycle.  Panel A represents the chemical structure of 
SAMe.  Note the key activated methyl group attached to the sulfur which is responsible for 
methyl donation.  Panel B is the methionine cycle in which SAMe is a key component.  ATP 
combines with methionine with the help of MAT to create SAMe which can then donate a 
methyl group as part of the transmethylation pathway.  SAH then cycles through the 
transsulfuration pathway. 
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Figure 4.  Polyamine Synthesis.  The synthesis of putrescine (Put) is catalyzed by the enzyme 
ornithine decarboxylase (ODC).  Then, SAMe is decarboxylated by SAMDC allowing SAMe to 
act as a propyl amine donor for both spermidine (Spd) and spermine (Spm) synthesis.  Spd and 
Spm can be interconverted by Spermidine/Spermine N
1
-Acetyltransferase (SSAT) and 
Polyamine oxidase (PAO). 
 
 
 
- 25 - 
 
Statement of Hypothesis 
Our laboratory previously demonstrated equivalent protection from APAP toxicity between 
SAMe and NAC in the C57BL/6 mouse model.  My thesis sought to deepen the mechanistic 
understanding of the observed protection.  To that end, I tested the following hypotheses in the 
current work.  First, SAMe levels will be decreased by APAP toxicity in both liver homogenate 
and subcellular fractions.  Second, the mechanism of SAMe prevention of oxidative stress with 
APAP overdose is due in part to protection of antioxidant enzyme function.  Third, SAMe given 
following APAP overdose will prevent declines in the protective polyamines Spd and Spm.  
Finally, SAMe will prevent 4-HNE adduction of proteins following APAP overdose.   
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Chapter II:  General Methods and Materials 
The C57BL/6 Mouse Model 
Through the work of previous doctoral studies (Cover et al., 2005b; Terneus et al., 2007), we 
were fortunate to have a well characterized animal model available for my thesis research.  
C57BL/6 mice have very similar metabolic profiles to humans with CYP2E1 being the 
predominant P450 responsible for metabolism of APAP in the mice (Bessems and Vermeulen, 
2001).  Additionally, the rate of sulfation and glucuronidation in the mice is roughly comparable 
to humans making them a good model to study toxicity due to APAP overdose (Bessems and 
Vermeulen, 2001).   
Male C57BL/6 mice were purchased from Hilltop Lab Animals Incorporated (Scottsdale, PA).  
Male mice were used to avoid any potential hormonal variations in APAP metabolism.  Animals 
included in the study were between 4-8 weeks of age and weighed 16-24 g.  Mice were 
maintained in a facility in compliance with the guidelines of the American Association for 
Accreditation of Laboratory Animal Care.  Mice were maintained at controlled temperature (21-
23°C), humidity (40-55%), and 12 hour light cycles (lights on 6:00 AM to 6:00 PM).  An 
acclimation period of 7 days was observed prior to the beginning of any experiment.  The 
animals received Purina rodent chow and water ad libitum.  The mice were fasted for 16 hours 
prior to any experiment to decrease available stores of GSH, but maintained free access to water. 
On the days of experiments, the mice were injected in the intraperitoneal (ip) cavity with Veh 
(water), SAMe, NAC, APAP, and/or a combination of either SAMe or NAC with APAP (S + A 
or N + A respectively).  The main focus of my research was on a recovery scenario whereby 
SAMe or NAC were given as an antidote following APAP injection.  This model most closely 
approximates someone who has overdosed on APAP and is entering the acute care setting.   
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Experimental Protocol 
Mice were randomly divided into the following groups:  Vehicle (Veh; 15 ml/kg water ip 
injection), SAMe or NAC (1.25 mmol/kg given as a 5 ml/kg injection), APAP (250 mg/kg given 
as 15 ml/kg ip injection), and SAMe or NAC given one hour following APAP administration.  
The dose of APAP chosen is equivalent to an average 70 kg individual swallowing 35 Extra 
Strength Tylenol tablets.  A review of the literature puts the dose of APAP used in these studies 
on the low end of what is currently being used.  For instance, some laboratories go as high as 750 
mg/kg APAP overdose to induce toxicity (Ramachandran and Raja, 2010).  Using a lower dose 
offers a better approximation of what is physiologically possible in humans. 
The collection times were 2, 4, and 6 hours following the initial administration of APAP.  Mice 
were anesthetized with carbon dioxide and blood collected by cardiac puncture with heparinized 
1 mL syringes to allow for analysis of plasma ALT activity.  Unless subcellular fractioning 
occurred, livers were placed in ice cold Krebs buffer (126 mM NaCl, 5 mM KCl, 3 mM MgSO4, 
3 mM Na2HPO4, 1 mM CaCl2; pH 7.4), blotted, and weighed.   
Comparison of SAMe-Cl and SAMe-toluene sulfonate Salts 
To ensure that SAMe was protective, and not the toluene sulfonate salt we were using in 
experiments, I conducted experiments with the chloride salt of SAMe.  I found comparable ALT 
and liver weight per 10 g body weight values for both treatment groups (Data not shown).  
Additionally, there was no observed difference in other parameters measured between the salts.  
Therefore, I conclude that SAMe is in fact the protective entity, not the toluene sulfonate salt. 
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Basic Assessment of Toxicity 
To normalize comparison among different experiments, certain baseline toxicity parameters were 
assessed.  Plasma alanine aminotransferase (ALT) activity is a common experimental measure of 
APAP hepatotoxicity.  Following necrosis of the centrilobular hepatocytes, ALT is released into 
the blood.  Human liver toxicity in APAP overdose is generally agreed upon as ALT activity 
over 1,000 IU/L (McClain et al., 1999).  Alanine aminotransferase (ALT) was assayed using a 
method based on the discontinued Sigma 505-P kit and described by the Harvison laboratory 
(Patel et al., 2011).  Additionally, liver weight was determined.  Necrosis caused by APAP 
creates oncotic pressure in the liver drawing water in and increasing the weight of the liver.   
General Protocol for Western Blotting 
Western blots were performed as follows:  Two hundred milligrams of liver was homogenized in 
1 mL ice cold Kreb’s buffer and protein levels were determined using the Bradford protein assay. 
A 100 µg protein aliquot was denatured by boiling for 5 minutes.  Samples were separated on a 
12.5% polyacrylamide gel and transferred to a nitrocellulose membrane (Whatman; Dassel, 
Germany).  Transfer efficiency was verified using MemCode® Reversible Protein Stain Kit 
(Thermo Scientific; Rockford, IL).  MemCode® staining was used to standardize the 
densitometry to total protein in each of the lanes.  The only exceptions to this were the MAT I/III 
and MAT II proteins that were standardized with GAPDH.  Protein staining was used in most 
cases because of the more reliable and consistent results obtained with staining compared with 
the typical housekeeping genes.   
The membranes were then blocked using a 5% (w/v) milk/TBST solution (10 mM Tris-HCl, 150 
mM NaCl, 0.1% Tween-20; pH 8.0) for 1 hour.  Membranes were then incubated overnight with 
constant shaking at 4°C in primary antibody prepared at the appropriate dilution in 5% (w/v) 
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milk/TBST.  The membranes were washed four times with TBST.  The appropriate secondary 
antibody was diluted in 5% (w/v) milk/TBST and incubated with the membrane for 1 hour.  All 
of the antibodies used in the current work can be found in Table 1 below.  The membrane was 
again washed with TBST and developed using Amersham
TM
 ECL
TM
 Western Blotting Detection 
Reagents (GE Healthcare; Buckinghamnshire, UK).  Densitometry was performed on each gel 
using the Image J software (NIH).  
Table 1.  Primary and secondary antibodies used in the current work. 
 
a,b,c,d
 Superscripts after the primary antibodies correspond with the superscripts found on the 
secondary antibodies below. 
*Selected abbreviations:  MAT (Methionine adenosyltransferase), ODC (Ornithine 
decarboxylase), 3-NT (3-nitro tyrosine), CPS-1 (Carbamoyl phosphate synthase-1). 
 
 
Statistical Analysis of Data 
All values are reported as the mean ± S.E.M. with n = 3-10 animals per group.  The final number 
of animals for each experiment is noted below in the results section.  Differences between the 
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groups were determined using a one-way ANOVA followed by a Tukey’s post-hoc test 
(SigmaStat; SPSS Inc. Chicago, IL).  Significant differences were assessed using  = 0.05.   
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Abstract 
Acetaminophen (APAP) is the leading cause of drug induced liver failure in the United States. 
Previous studies in our laboratory have shown that S-adenosyl methionine (SAMe) is protective 
for APAP hepatic toxicity.  SAMe is critical for glutathione synthesis and transmethylation of 
nucleic acids, proteins and phospholipids which would facilitate recovery from APAP toxicity. 
SAMe is synthesized in cells through the action of methionine adenosyltransferase (MAT). This 
study tested the hypothesis that total hepatic and subcellular SAMe levels are decreased by 
APAP toxicity. Studies further examined MAT expression and activity in response to APAP 
toxicity. Male C57BL/6 mice (16-22 grams) were treated with vehicle (Veh; water 15ml/kg ip 
injections), SAMe (1.25 mmol/kg), 250 mg/kg APAP (15 ml/kg, ip),  or SAMe administered one 
hour after APAP injection (SAMe and S + A). Hepatic tissue was collected 2, 4, and 6 hours 
after APAP administration. Levels of SAMe and its metabolite S-adenosylhomocysteine (SAH) 
were determined by HPLC analysis. MAT expression was examined by Western blot.   MAT 
activity was determined by fluorescence assay.  Total liver SAMe levels were depressed at 4 
hours by APAP overdose, but not at 2 or 6 hours.  APAP depressed mitochondrial SAMe levels 
at 4 and 6 hours relative to the Veh group. In the nucleus, levels of SAMe were depressed below 
detectable limits 4 hours following APAP administration.  SAMe administration following 
APAP (S + A) prevented APAP associated decline in mitochondrial and nuclear SAMe levels.  
In conclusion, the maintenance of SAMe may provide benefit in preventing damage associated 
with APAP toxicity. 
KEY WORDS:  S-adenosyl-L-methionine, Acetaminophen, Hepatotoxicity, S-
adenosylhomocysteine, Methionine Adenosyltransferase 
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Introduction 
Acetaminophen (APAP) is the leading cause of drug induced liver disease in the United States 
resulting in over 56,000 emergency room visits and approximately 500 deaths each year 
(Nourjah et al., 2006).  One of the problems associated with APAP toxicity is the wide 
availability of the drug.  APAP is present in over 180 over the counter (OTC) products, which 
increases the probability of accidental overdose.  Acute overdose of APAP leads to severe 
hepatic centrilobular necrosis (Boyd and Bereczky, 1966; Golden et al., 1981).  Rapid treatment 
with N-acetylcysteine (NAC) is currently the clinical treatment for APAP overdose.   
The toxicity of APAP is mediated through its biotransformation into N-acetyl-p-
benzoquinoneimine (NAPQI) by cytochrome P450 2E1, 3A4, and 1A2 (Corcoran et al., 1980; 
Dahlin et al., 1984; Patten et al., 1993).  NAPQI is a strong electrophile that rapidly adducts 
sulfhydryl groups like those found on reduced glutathione (GSH) (Streeter et al., 1984).  GSH 
depletion by NAPQI precedes APAP toxicity (Larrauri et al., 1987).  In addition to adducting 
proteins, NAPQI also induces mitochondrial dysfunction leading to a severe energy debt and the 
formation of reactive oxygen species (ROS) that induce further damage in the hepatocytes 
(Andersson et al., 1990).   
The current treatment for APAP overdose is N-acetylcysteine (NAC). NAC functions by 
replenishing cellular stores of cysteine which is involved in the rate-limiting step in the 
formation of GSH.  NAC has been demonstrated to reduce protein adduction in response to 
APAP overdose (Corcoran et al., 1985).  Also, NAC reduces mitochondrial dysfunction and 
reactive oxygen generation in hepatocytes following APAP overdose (Reid et al., 2005).  In 
order to be effective as a treatment, however, NAC must be administered within 8-10 hours 
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following APAP overdose, making the study of alternative therapies attractive (Smilkstein et al., 
1988).   
Currently, S-adenosyl-L-methionine (SAMe) is available over the counter and has gained 
acceptance as beneficial for depression and alcoholic liver disease (Purohit et al., 2007; Williams 
et al., 2005).  SAMe is a ubiquitous cofactor in a variety of biological reactions.  SAMe is found 
in most tissues and is produced at a rate of 6-8 g per day in the liver.  The production of SAMe is 
catalyzed by methionine adenosyltransferase (MAT) (Lu, 2000).  MAT1A is expressed 
constitutively in the adult liver and encodes the 1 subunit which composes MAT I (tetramer) 
and MAT III (dimer).  The gene coding for MAT II is MAT2, which is widely distributed 
throughout the body with the exception of the adult liver (Kotb et al., 1997).  However, MAT II 
is expressed in the adult liver during liver regeneration and hepatic cancer (Martinez-Chantar et 
al., 2003; Paneda et al., 2002).  Furthermore, MAT1A expression is increased during liver 
regeneration following partial hepatectomy (Chen et al., 2004). 
The protective action of SAMe upon the liver is hypothesized to be mediated via the 
transmethylation and transsulfuration pathways.  SAMe is the principal biological methyl donor 
in cells.  Following methyl group donation, SAMe becomes S-adenosylhomocysteine (SAH) that 
can enter the transsulfuration pathway leading to replenishment of cellular GSH (Finkelstein, 
2000).   Alterations in either SAMe or its ratio with SAH have been associated with toxicant 
exposure. For example,  SAMe levels were decreased in humans with alcoholic liver disease 
(Purohit et al., 2007).  Furthermore, any decline in SAMe or decrease in the ratio of SAMe:SAH 
has been demonstrated to inhibit cellular transmethylation reactions (Purohit et al., 2007) as  
SAH is a competitive inhibitor of transmethylation reactions (Kharbanda 2007). Previous 
research by our laboratory and others has demonstrated that SAMe protects against APAP 
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induced hepatotoxicity when administered just prior to APAP overdose (Bray et al., 1992; 
Terneus et al., 2007). More recent studies have documented that in a more clinically relevant 
experimental model, SAMe administered 1 hour after APAP overdose was protective to the liver 
(Terneus et al., 2008). 
In our laboratory, SAMe and NAC displayed a comparable level of protection, when compared 
on the basis of a mmol/kg dose, for APAP overdose in mice (Terneus et al., 2008).  However, the 
mechanism for SAMe protection of APAP toxicity remains to be elucidated.  While decreases in 
SAMe have been linked to liver damage, little research has been done to examine the effects of 
APAP toxicity on intracellular SAMe levels.  A decrease in intracellular SAMe levels following 
APAP overdose would have deleterious effects on DNA methylation, phospholipid formation 
and GSH synthesis. Additionally, given that expression of MAT appears to be required for liver 
regeneration following damage, the exploration of APAP overdose effects on MAT levels 
warrants further study.  Therefore, the purpose of the current study was to investigate the effect 
of APAP overdose on hepatic, 15,000 x g supernatant, nuclear and mitochondrial SAMe levels, 
as well as alterations of hepatic MATI/III and MATII.  By examining these components of 
SAMe metabolism, the present study hopes to shed light on the mechanism of SAMe protection 
against APAP toxicity. 
Methods and Materials 
Materials.  SAMe toluene sulfonate salt as used in all experiments (Sigma Chemical Co., St. 
Louis, MO).  The ALT reagent kit (TR-71021) was purchased from Thermo Electron 
Corporation (Louisville, CO).  All solvents were HPLC grade and other reagents were of 
comparable quality and purchased from Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific 
(Pittsburgh, PA).   
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Animals.  Male C57BL/6 mice were obtained from Hilltop Lab Animals Inc. (Scottsdale, PA).  
Animals included in the study were between 4-8 weeks of age and weighed 16-24 g.  Mice were 
maintained in a facility in compliance with the American Association for Accreditation of 
Laboratory Animal Care.  Mice were maintained at controlled temperature (21-23°C), humidity 
(40-55%), and 12 hour light cycles (lights on 6:00 AM to 6:00PM).  An acclimation period of 7 
days was observed prior to the beginning of any experiment.  The animals received Purina rodent 
chow and water ad libitum.  The mice were fasted for 16 hours prior to any experiment, but 
maintained free access to water. 
SAMe and NAC Treatment Following APAP Overdose.  Mice were randomly allocated into the 
following groups:  vehicle (Veh; 15 ml/kg water by intraperitoneal (ip) injection), SAMe (1.25 
mmol/kg 5ml/kg ip injection), APAP (250 mg/kg 15ml/kg ip injection, and SAMe administered 
1 hour after APAP (S + A; doses same as previously listed).   Mice treated with NAC were 
randomly allocated into Veh, NAC (1.25 mmol/kg with 5 ml/kg ip injection), APAP, and N + A.   
SAMe and NAC were administered 1 hour following APAP.  Mice were anesthetized with 
carbon dioxide 2, 4, and 6 hours after APAP administration with SAMe treatment, and 4 hours 
following APAP treatment when NAC was used as a comparison for SAMe.  Blood was 
collected by cardiac puncture in heparin-rinsed 1 ml syringes for determination of serum ALT 
activity, which serves as an indicator of liver injury.  Livers were then isolated and placed in ice 
cold Krebs buffer (126 mM NaCl, 5 mM KCl, 3 mM MgSO4, 3 mM Na2HPO4, 1 mM CaCl2; pH 
7.4), blotted, and weighed.    
Mitochondrial Isolation.  Mitochondria were isolated using a modification of a previously 
published protocol (Gogvadze et al., 2004).  Briefly, the liver was isolated, blotted, weighed and 
placed in Mitochondrial Isolation Buffer A (225 mM sucrose, 3 mM KH2PO4, 5 mM MgCl2, 20 
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mM KCl, 20 mM triethanolamine, 2 mM EGTA; pH 7.4).  The liver was minced and 
homogenized in a Dounce homogenizer on ice.  Following homogenization, the liver was 
centrifuged at 600 x g for 10 minutes.  The resultant pellet was discarded and the supernatant 
was centrifuged at 15,000 x g for 5 minutes.  After the final centrifugation, the supernatant was 
retained for analysis of SAMe levels.  The pellet containing the mitochondria was resuspended in 
Mitochondrial Isolation Buffer B (Same as Buffer A except lacking EGTA) for a final 
concentration of 1 mg tissue weight/1 ml Buffer B.  Samples were stored at -80°C until analysis. 
Nucleus Isolation.  The protocol for isolating the nuclei of liver cells was adapted from Graham 
(2001).  Briefly, liver was homogenized in ice cold Nuclear Isolation Medium (0.25 M sucrose, 
25 mM KCl, 5 mM MgCl2, and 10 mM Tris-Cl; pH 7.4) using a Dounce homogenizer and 
adjusted to a final 3 mL volume.  The homogenate was centrifuged at 800 x g, the supernatant 
discarded, new buffer was added and centrifuged at 800 x g and the supernatant discarded.  The 
pellet was resuspended in 1 mL Nuclear Isolation Medium followed by 2 mL of Sucrose Density 
Barrier (1.15 M sucrose, 10 mM KCl, 2.5 mM MgCl2, and 5 mM Tris-Cl; pH 7.4) and vortexed.  
Six mL of Sucrose Density Barrier was then layered under the homogenate and centrifuged for 1 
hour at 100,000 x g.  The pellet was resuspended in 1 mL Nuclear Isolation Medium and stored 
at -80°C until use.   
HPLC Analysis of Hepatic SAMe Levels.  A 200 mg aliquot of liver was homogenized on ice in 
0.4 mM HClO4 and adjusted to a final 1 ml volume.  Mitochondrial and 15,000 x g supernatant 
suspensions were added to an equal volume of 0.4 mM HClO4 to precipitate protein.  Nuclear 
samples were concentrated by lyophilizing the 1 ml of sample (total liver weight 600-900 mg) 
and reconstituting the sample in 125 µl 0.4 mM HClO4.  The samples were then centrifuged at 
10,000 x g at 4°C and filtered through 0.45 µM Millex®-HV filters (Millipore; Billericia, MD).  
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A 20 µl sample of the filtrate was analyzed for whole liver, mitochondrial, and 15,000 x g 
supernatant fractions, while 40 µl of sample was required for detection of nuclear SAMe levels.  
SAMe and SAH levels were detected using a Beckman Coulter HPLC system (Fullerton, CA) 
with a 126 Solvent Module and a 166 Variable Wavelength Detector.  The column was a YMC 
ODS-AQ 3 µm 120 Å 4.6x150 mm column. The mobile phase was a gradient at a flow of 1 
ml/min (Waters Corporation; Milford, MA).  The mobile phase gradient program was 8 minutes 
of 90:10 A:B followed by 12 minutes of 60:40 A:B.  Mobile phase A consisted of  8 mM 1-
heptane sulfonic acid sodium salt and 50 mM sodium phosphate monobasic (pH 3).  Mobile 
phase B was 100% HPLC grade methanol.  The wavelength for detection was 254 nm (Wang et 
al., 2001).    
Analysis of MAT I/II/III Expression in Mouse Liver.  Western blot analysis was conducted to 
examine expression of MAT I/III and MAT II.  Approximately 200 mg of liver was 
homogenized in 1 mL ice cold Krebs buffer and protein levels were determined using the 
Bradford protein assay. A 100 µg protein aliquot was denatured by boiling for 5 minutes.  
Samples were separated on a 12.5% polyacrylamide gel and transferred to a PVDF membrane 
(Pall Corporation; Pensacola, FL).  Transfer efficiency was verified using MemCode® 
Reversible Protein Stain Kit (Thermo Scientific; Rockford, IL).  The membrane was then 
blocked using a 5% (w/v) milk/TBST solution (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-
20; pH 8.0) for 1 hour.  Membranes were next incubated overnight with constant shaking at 4°C 
in antibody for MAT I/III (sc-28029, Santa Cruz Biotechnology; Santa Cruz, CA) or MAT II (sc-
28031, Santa Cruz Biotechnology; Santa Cruz, CA) each at 1:1000 dilution in 5% (w/v) 
milk/TBST.  The membranes were washed four times with TBST.  The donkey anti-goat HRP 
secondary antibody (sc-2020, Santa Cruz Biotechnology; Santa Cruz, CA) was diluted 1:3000 
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and incubated with the membrane for 1 hour.  The membrane was again washed with TBST and 
developed using Amersham
TM
 ECL
TM
 Western Blotting Detection Reagents (GE Healthcare; 
Buckinghamnshire, UK).  Blots were then reprobed with GAPDH as a loading control (2275-PC-
100, Trevigen; Gaithersburg, MD).  Goat anti-rabbit HRP secondary antibody was used to 
develop the blots (sc-2004, Santa Cruz Biotechnology; Santa Cruz, CA).  Densitometry was 
performed on each gel.  
Determination of MAT Activity.  An endpoint fluorometric assay for determination of MAT 
activity developed by Wang, et al. (2003) was modified for a high throughput assay using a 
fluorescent plate reader.  The assay measures the formation of scopoletin through MAT activity.  
A standard curve was constructed from scopoletin with a lower detection limit of 50 pmol.  The 
protocol of Wang was followed except at the end when the extracted scopoletin was transferred 
to a 96 well plate and read using a BioTeck Synergy 2 (BioTek Instruments; Winooski, VT) with 
excitation and emission at 347 and 415 nm, respectively. 
Statistical Analysis.  Values represent Mean ± S.E.M. with n=3-10 animals/group.  Differences 
in the groups were analyzed using a one-way ANOVA followed by a Tukey’s post-hoc test 
(SigmaStat; SPSS Inc. Chicago, IL).  All statistical analyses were conducted using a 95% 
confidence interval.   
Results 
The body weights of the animals were not significantly different between groups (Table 2).  In 
addition, liver to body weight ratios were diminished in the S + A group 4 hours after APAP 
overdose when compared to APAP treated mice (Table 2).  However, the same reduction in the 
liver to body weight ratio was not observed when the livers were collected at 6 hours following 
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APAP overdose (Table 2).  To provide a comparison for the current standard of treatment for 
APAP overdose, NAC (1.25 mmol/kg) was administered 1 hour following APAP overdose and 
livers collected 4 hours following APAP overdose.  When adjusted for body weight, NAC 
prevented the rise in liver weight that typically serves as an indicator of APAP toxicity (Table 3).  
These liver weight results indicate that equimolar doses of SAMe and NAC (1.25 mmol/kg) are 
able to reduce the liver to body weight ratio when administered following APAP overdose. 
Table 2.  Body weight and liver weight per 10 g body weight changes following  APAP  and 
SAMe. 
Mice were randomly allocated into the following groups: Veh (water), SAMe (1.25 mmol/kg), 
APAP (250 mg/kg), SAMe 1 hour after APAP (S + A).  SAMe and APAP were administered by 
ip injection. Values represent Mean ± S.E.M. (n=5-10). Values were measured 2, 4 or 6 hours 
post APAP or Veh injection.  
 
abc
  Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  
 
 
 
 
 Group Body Weight (g) Liver weight /10 g body weight 
S
A
M
e 
2
 
h
 
 
Veh 24.00 ± 0.00
a 
0.461 ± 0.00552
a 
SAMe 23.60 ± 0.40
a 
0.400 ± 0.0256
a 
APAP 24.40 ± 0.40
a 
0.456 ± 0.0231
a 
S + A 22.80 ± 0.80
a 
0.467 ± 0.0108
a 
S
A
M
e 
4
 
h
  
Veh 20.80 ± 0.49
a 
0.395 ± 0.0164
a
 
SAMe 20.40 ± 0.75
a 
0.415 ± 0.00650
ac 
APAP 20.80 ± 0.49
a
 0.477 ± 0.0102
b 
S + A 20.80 ± 0.49
a 
0.464 ± 0.0177
c 
S
A
M
e 
6
 
h
  
Veh 18.40 ± 0.40
a 
0.363 ± 0.00475
a 
SAMe 19.20 ± 0.49
a 
0.385 ± 0.00858
a 
APAP 18.40 ± 0.40
a 
0.486 ± 0.0192
b 
S + A 19.00 ± 0.58
a 
0.470 ± 0.0187
b 
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Table 3.  The effect of NAC and APAP on body and liver weight per 10 g body weight  
 Group Body Weight (g) Liver weight/10g body weight 
N
A
C
 4
 h
  Veh 20.00 ± 0.63
a 
0.416 ± 0.0296
a 
NAC 19.60 ± 0.75
a 
0.443 ± 0.00492
a 
APAP 18.00 ± 0.00
a 
0.547 ± 0.0150
b 
N + A 20.00 ± 0.89
a 
0.466 ± 0.0101
a 
Mice were randomly allocated into the following groups: Veh (water), NAC (1.25 mmol/kg), 
APAP (250 mg/kg), NAC 1 hour after APAP (N + A).  NAC and APAP were administered by ip 
injection. Values represent Mean ± S.E.M. (n=5-10). Values were measured 4 hours post APAP 
or Veh.
 
 
ab
 Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  
 
 
Plasma ALT is a common measure of liver toxicity as ALT is released into the serum following 
damage to the liver.  Prior experiments on APAP toxicity have indicated that toxicity induces a 
steady increase in plasma ALT between 2 and 6 hours.  Plasma ALT levels typically range 
between 2000 and 6000 IU/L for the time periods studied in mice (Andringa et al., 2008; Hinson 
et al., 2002; Knight et al., 2003).  Toxicity from APAP overdose was demonstrated two hours 
following APAP administration (Figure 5).  At 4 hours following APAP administration, 
equivalent doses of SAMe and NAC protect the liver as indicated by a significant decrease in 
serum ALT when compared to the APAP treatment group (Figure 5).  When the livers were 
collected 6 hours following APAP overdose, SAMe treatment was unable to reduce serum ALT 
levels back to that of the Veh treatment group, although SAMe was able to significantly lower 
serum ALT levels compared with the APAP treatment group (Figure 5).  NAC significantly 
reduced ALT when administered 1h following APAP (Figure 5).   
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Figure 5.  The effect of SAMe and NAC on serum ALT levels following APAP overdose in 
C57BL/6 mice.  In panel A of the figure, mice were randomly allocated into the following 
groups: Veh (water), SAMe (1.25 mmol/kg), APAP (250 mg/kg), SAMe 1 hour after APAP (S + 
A).  Plasma was collected 2, 4 and 6 hours following the initial APAP overdose.  Panel B of the 
figure consisted of mice allocated into groups of Veh (water), NAC (1.25 mmol/kg), APAP (250 
mg/kg), and NAC administered 1 hour following APAP (N + A).  Serum was collected 4 hours 
following APAP administration.  Values represent mean ± S.E.M. with n=5-10 mice/group.  
Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results. 
 
Hepatic SAMe levels were measured following APAP overdose because perturbations in SAMe 
can inhibit transmethylation and transsulfuration reactions (Lu, 2000).  At 4 and 6 hours 
following APAP administration SAMe levels were significantly (p<0.05) decreased compared to 
the Veh groups (Figure 6).  Administration of SAMe 1 hour following APAP prevented the 
decrease in liver homogenate SAMe levels (Figure 6).    Peak SAMe levels were observed in the 
SAMe and S + A groups 1 hour following SAMe administration (Figure 6).  Mice were collected 
at 1 hour after SAMe administration but 2 hours following APAP administration (Figure 6).  In 
Table 4 it can be observed that levels of SAH significantly decreased 2 hours following APAP 
administration when compared to the Veh group.  In addition, the ratio of SAMe:SAH increases 
in the APAP treatment group at 2 hours (Figure 6).  Also, by 6 hours the ratio of SAMe:SAH in 
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the SAMe group decreases because of the drop in SAMe levels as the levels of SAH remain 
constant (Figure 6; Table 4). 
 
Figure 6.  Alterations of SAMe levels following APAP overdose.  C57BL/6 mice were 
randomly allocated into Veh (water), SAMe (1.25 mmol/kg), APAP (250 mg/kg), and SAMe 
administered 1 hour after APAP (S + A).  Livers were collected at 2, 4 and 6 hours following 
APAP overdose and processed for analysis of SAMe levels by HPLC.  Values represent mean ± 
S.E.M.  Panel A represents SAMe levels (nmol/g tissue) following APAP administration, while 
panel B represents the ratio of SAMe:SAH.  Different letters denote statistical differences 
(p<0.05), while groups with the same letters indicate no difference in the results. 
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Table 4.  The Effect of SAMe on Total Hepatic SAH levels following APAP overdose. 
Mice were randomly allocated into the following groups: Veh (water), SAMe (1.25 mmol/kg), 
APAP (250 mg/kg), SAMe 1 hour after APAP (S + A). SAMe  and APAP were administered by 
ip injection. Values represent Mean ± S.E.M. (n=5-10). SAH levels were measured in liver 
homogenate  2, 4  or 6  hours post APAP or Veh.
 
 
ab
 Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results. 
 
 
As would be expected, administration of NAC did not increase SAMe levels in the NAC group 
(Figure 7).  Perhaps the most interesting finding in the NAC study was that NAC administration 
following APAP prevented a significant decrease in the levels of SAMe in the N + A group 
(Figure 7).  No changes were observed in SAH levels following APAP administration (Table 5).  
The ratio of SAMe:SAH in the APAP treatment groups is decreased when compared to the Veh 
group (Figure 7).  Administration of NAC following APAP was not able to significantly increase 
the ratio of SAMe:SAH when compared with the APAP at 4 hours (Figure 7).  SAMe was also 
unable to increase the ratio of SAMe:SAH at the same time period (Figure 6). 
 
 
 Group  Liver SAH Levels (nmol/g tissue) 
S
A
M
e 
2
 
h
 
 
Veh 67.176 ± 1.540
a 
SAMe 75.404 ± 9.352
a 
APAP 34.630 ± 9.046
b 
S + A 49.118 ± 2.549
ab 
S
A
M
e 
4
 
h
  
Veh 44.130 ± 2.110
a 
SAMe 61.770 ± 4.310
b
 
APAP 42.310 ± 4.410
a 
S + A 40.580 ± 2.100
a 
S
A
M
e 
6
 
h
  
Veh 51.290 ± 5.470
ab 
SAMe 57.810 ± 4.400
ab 
APAP 54.630 ± 2.940
a 
S + A 64.250 ± 0.840
b 
- 60 - 
 
 
Figure 7.  The observed effects of NAC on SAMe levels in the liver after APAP overdose.  
C57BL/6 mice were randomly allocated into Veh (water), NAC (1.25 mmol/kg), APAP (250 
mg/kg), and NAC administered 1 hour following APAP (N + A).  Livers were collected 4 hours 
following administration of APAP and processed for determination of SAMe levels via HPLC.  
Panel A represents SAMe levels when NAC was given following APAP overdose, and panel B 
represents the ratio of SAMe:SAH under the same experimental conditions.  All values represent 
mean ± S.E.M. with n=5 mice/group. Different letters denote statistical differences (p<0.05), 
while groups with the same letters indicate no difference in the results. 
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Table 5.  The Effect of NAC and APAP on Hepatic SAH levels. 
 
 Groups Liver Homogenate SAH Levels (nmol/g tissue) 
N
A
C
 4
 h
 
Veh 59.230 ± 4.070
a 
NAC 60.090 ± 8.500
a 
APAP 39.420 ± 11.020
a 
N + A 59.710 ± 3.140
a 
Mice were randomly allocated into the following groups: Veh (water), NAC (1.25 mmol/kg), 
APAP (250 mg/kg), NAC 1 hour after APAP (N + A).  NAC and APAP were administered by ip 
injection. Values represent Mean ± S.E.M. (n=5-10). SAH levels were measured in liver 
homogenate 4   hours post APAP or Veh. 
 
a
 Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  
 
 
 
After analyzing whole liver levels of SAMe, the experiment next proceeded to measuring 
subcellular levels of SAMe.  First, the effect of APAP overdose on hepatic mitochondrial SAMe 
levels was analyzed.  Mitochondria are known to have SAMe transporters (Aqrimi et al., 2004).  
Levels of SAMe were decreased at both 4 and 6 hours following APAP overdose in the APAP 
treatment groups but not at 2 hours following APAP administration (Figure 8).  At 2, 4, and 6 
hours following APAP overdose, administration of SAMe after APAP causes a significant 
increase in levels of mitochondrial SAMe when compared to the Veh group (Figure 8).  
Mitochondrial SAH levels are decreased significantly 4 hours following APAP overdose, but 
remain unchanged for all other groups and time periods analyzed (Table 6).  Additionally, the 
ratio of SAMe:SAH is increased in the S + A group for the mitochondria at all time periods 
(Figure 8).  One other aspect of note, is that the ratio of SAMe:SAH in the mitochondria is not 
decreased in the APAP treatment group (Figure 8).   
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Figure 8.  Examination of the effect of exogenous SAMe on levels of SAMe in liver 
mitochondria of C57BL/6 mice.  Mice were randomly divided in to Veh (water), SAMe (1.25 
mmol/kg), APAP (250 mg/kg), and SAMe administered 1 hour following APAP (S + A).  Livers 
were collected and mitochondria isolated at 2, 4 and 6 hours following APAP overdose.  Levels 
of SAMe and SAH were determined by HPLC.  Panel A represents levels of mitochondrial 
SAMe when SAMe was administered following APAP overdose.  Panel B is the ratio of 
SAMe:SAH in the same treatment groups.  All values represent mean ± S.E.M. with n=5 
mice/group.  Different letters denote statistical differences (p<0.05), while groups with the same 
letters indicate no difference in the results. 
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 Table 6.  Mitochondrial and 15,000 x g supernatant SAH levels in animals treated with 
APAP followed 1 hour later by SAMe 
Mice were randomly allocated into the following groups: Veh (water), SAMe (1.25 mmol/kg), 
APAP (250 mg/kg), SAMe 1 hour after APAP (S + A). SAMe and APAP were administered by 
ip injection. Values represent Mean ± S.E.M. (n=5-10). Mitochondrial and 15,000 x g 
supernatant SAH levels were measured  2, 4  or 6  hours post APAP or Veh.
 
 
abc
 Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  
 
Levels of 15,000 x g supernatant SAMe were determined in addition to the levels of 
mitochondrial SAMe.  Hepatic 15,000 x g supernatant SAMe levels were significantly decreased 
at 4 and 6 hours following APAP overdose (Figure 9).  The drop in SAMe observed in the APAP 
treatment group at 4 and 6 hours was prevented by SAMe administration following APAP 
overdose (Figure 9). 15,000 x g supernatant SAH levels were decreased in the SAMe and S + A 
groups at two hours (Table 6).  SAH levels were also significantly depressed at 4 and 6 hours in 
the 15,000 x g supernatant APAP treatment groups and this was reversed by administration of 
SAMe following APAP overdose (Table 6).   In the S + A group at both 2 and 4 hours the ratio 
of SAMe:SAH was significantly increased (Figure 9).  In the APAP treatment group at 6 hours, 
there was no observed alteration of the ratio of SAMe:SAH (Figure 9). 
 
Group 
Mitochondria SAH Levels 
(nmol/g tissue) 
15,000 x g SAH Levels (nmol/g 
tissue) 
S
A
M
e 
2
 
h
 
 
Veh 8.329 ± 0.250
a 
20.603 ± 1.146
a 
SAMe 9.237 ± 0.810
a 
7.446 ±0.212
b 
APAP 7.488 ± 1.642
a 
16.856 ± 3.736
ac 
S + A 9.667 ± 0.855
a 
5.315 ± 0.656
d 
S
A
M
e 
4
 
h
  
Veh 11.359 ± 0.747
a 
23.871 ± 1.804
a 
SAMe 11.609 ± 1.342
a 
22.147 ± 2.184
a 
APAP 3.633 ± 0.389
b 
3.911 ± 0.334
b 
S + A 8.544 ± 0.361
a 
8.991 ± 0.481
c 
S
A
M
e 
6
 
h
  
Veh 7.427 ± 0.743
a 
26.267 ± 1.717
a 
SAMe 6.013 ± 0.618
a 
29.343 ± 2.493
a 
APAP 3.006 ± 0.311
a 
8.218 ± 3.484
b 
S + A 6.377 ± 1.379
a 
13.700 ± 3.719
c 
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Figure 9.  Alterations of 15,000 x g supernatant fraction SAMe levels following APAP 
overdose in C57BL/6 mice.  The mice were randomly allocated into Veh (water), SAMe (1.25 
mmol/kg), APAP (250 mg/kg), and SAMe administered 1 hour following APAP (S + A).  Livers 
were collected at 2, 4 and 6 hours following APAP administration and processed for collection of 
the 15,000 x g supernatant.  Levels of SAMe were determined by HPLC.  Panel A represents 
SAMe levels in the 15,000 x g supernatant fraction, while panel B is the ratio of SAMe:SAH in 
the same samples.  All values represent mean ± S.E.M. with n=5 mice/group.  Different letters 
denote statistical differences (p<0.05), while groups with the same letters indicate no difference 
in the results. 
 
APAP treatment altered subcellular hepatic nuclear levels of SAMe. No change was observed in 
nuclear SAMe levels 4 hours following APAP administration between Veh, SAMe and S + A 
groups. The detection limit was 12.5 pmol and the APAP treated group all had nuclear SAMe 
levels below the detection limit of 12.5 pmol (Figure 10).  Levels of SAH could be determined 4 
hours following APAP overdose, but there was no significant change observed in any of the 
groups (Table 7).  The ratio of SAMe:SAH in the nuclei of the liver cells was also unchanged 
when observed at 4 hours (Figure 10).  The ratio for the APAP group could not be determined 
because of the lack of SAMe data. 
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Figure 10.  Alterations of nucleus SAMe levels following APAP overdose in C57BL/6 mice.  
Mice were randomly put into Veh (water), SAMe (1.25 mmol/kg), APAP (250 mg/kg), or SAMe 
administered 1 hour following APAP groups.  Livers were collected at 4 hours and nuclei 
isolated.  SAMe levels were determined by HPLC analysis.  All groups had n=3-5 and values are 
listed as mean ± S.E.M.  Panel A represents levels of SAMe in the nucleus of cells following 
APAP overdose, and panel B represents the ratio of SAMe:SAH in the same groups.  SAMe 
levels in the APAP treatment group were below the current detection limit of 12.5 pmol (ND 
group).  Different letters denote statistical differences (p<0.05), while groups with the same 
letters indicate no difference in the results. 
 
Table 7.  Levels of SAH in the nucleus following APAP overdose. 
Mice were randomly allocated into the following groups: Veh (water), SAMe (1.25 mmol/kg), 
APAP (250 mg/kg), SAMe 1 hour after APAP (S + A). SAMe  and APAP were administered by 
ip injection. Values represent Mean ± S.E.M. (n=5-10). Nuclear SAH levels were measured  4 
and  6  hours post APAP or Veh treatment. 
 
 
a
 Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  
 
Analysis of MAT I/III expression in the liver indicates that there is a significant decrease in the 
levels of MAT I/III in the APAP group when compared to the Veh group 2 and 4 hours 
following APAP administration (Figure 11).  The administration of SAMe 1 hour after APAP 
 Group Nucleus SAH Levels (nmol/g tissue) 
S
A
M
e 
4
 
h
 
Veh 0.109 ± 0.0163
a 
APAP 0.159 ± 0.0122
a 
SAMe 0.143 ± 0.0279
a 
S + A 0.167 ± 0.0272
a 
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increased levels of MAT I/III back to Veh level at 2 and 4 hours following APAP overdose 
(Figure 11).  The presence of MAT II was not detected in hepatic tissue 2 and 4 hours following 
APAP overdose (Figure 11).  Protein transfer was confirmed by staining as described in Methods 
and Materials and recombinant MAT II protein was used to confirm the viability of the MAT II 
antibody (Figure 11).   
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Figure 11.  MAT I/II/III expression in hepatic tissue 2 hours and 4 hours following APAP 
overdose in C57BL/6 mice.  Hepatic tissue was collected after administration of Veh (water), 
1.25 mmol/kg SAMe, 250 mg/kg APAP, and SAMe 1 hour following APAP.  Each lane was 
loaded with 100 µg protein and detection was accomplished with chemiluminescence.  Panel A 
of the figure represents the density of the individual MAT I/III bands expressed as % Veh (n=3-5 
animals/group).  Values represent mean ± S.E.M. Different letters denote statistical differences 
(p<0.05), while groups with the same letters indicate no difference in the results.  Panel B is a 
representative blot 2 hours following APAP administration.  Lanes 1, 2, and 3 represent Veh 
samples.  Lanes 4, 5, and 6 represent SAMe samples.  Lanes 7 and 8 represent APAP samples, 
while 9 and 10 represent S + A treatment groups.  Panel C is a representative blot 4 hours 
following APAP administration.  Lanes depicted are as follows:  Veh (1 and 2), SAMe (3 and 4), 
APAP (5 and 6), and S + A (7 and 8).  Panel D is a representative example of MAT II expression 
4 hours following APAP administration.  Lane assignments include:  recombinant MAT II (1), 
Veh (2 and 3), SAMe (4 and 5), APAP (6 and 7), and S + A (8 and 9).  Similar blots were 
conducted for MAT II expression 2 hours following APAP administration with lack of 
expression also observed (data not shown).   
 
MAT activity was significantly increased in the APAP treatment group when compared to the 
SAMe and S + A groups 2 hours following administration of APAP (Figure 12).  Although the 
trend is there, the Veh group was not significantly elevated compared to the SAMe and S + A 
groups at 2 hours (Figure 12).  No differences were observed in MAT activity 4 hours following 
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APAP overdose (Figure 12).  When taken together with the 2 hour MAT expression data, it is 
observed that MAT activity in the SAMe and S + A groups decrease compared to the APAP 
group, while expression of MAT in the APAP group is decreased 2 hours following APAP 
administration. 
 
 
Figure 12.  MAT activity alterations following APAP overdose.  Mice were allocated at 
random into Veh (water), SAMe (1.25 mmol/kg), APAP (250 mg/kg), or SAMe administered 1 
hour following APAP groups.  Livers were collected 2 and 4 hours following APAP injection 
and MAT activity was determined by an endpoint fluorescence assay measuring pmol of 
scopoletin formed per minute per mg protein.  Values represent mean ± S.E.M. (n=5 mice per 
group).  Different letters denote statistical differences (p<0.05), while groups with the same 
letters indicate no difference in the results. 
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Discussion 
SAMe has been demonstrated to be an effective treatment for APAP overdose in mouse animal 
models (Stramentinoli et al., 1979; Valentovic, et al., 2004).  Although it is known that SAMe 
can participate in the replenishment of GSH through the transsulfuration pathway (Lu, 1998), 
other mechanisms of protection remain to be explored.  In order to gain an understanding of 
SAMe metabolism in the liver following APAP overdose, the purpose of the current study was to 
analyze hepatic SAMe and SAH levels.  The observed decrease in SAMe levels following APAP 
overdose could prevent any protection that SAMe could afford, and also could act as a precursor 
to APAP toxicity, much as the depletion of GSH precedes APAP toxicity (Moore et al., 1985).  
In addition, the observed decrease in MAT I/III expression in the liver at 4 hours would lead to 
SAMe depletion following APAP overdose.  
SAMe is the primary methyl donor in cells and is capable of methylating phospholipids, proteins, 
and nucleic acids.  Polyamine synthesis is dependent on adequate cellular SAMe levels (Lieber 
and Packer, 2002).  Studies of the effects of toxicity on SAMe levels in the cell are lacking, 
especially in the area of subcellular analysis of SAMe levels.  Perturbations in the ratio of 
SAMe:SAH can inhibit transmethylation reactions and conceivably the ability of SAMe to 
protect against APAP toxicity (Finkelstein et al., 1974).  In the current study of total liver SAMe, 
the ratio of SAMe:SAH  was increased in the  S + A group at two hours following APAP 
administration (Figure 6).  The levels of SAMe were decreased in whole liver 4 and 6 hours after 
APAP treatment, which would inhibit crucial transmethylation reactions.  When the ratios of 
SAMe:SAH in liver homogenate was calculated there was an observed increase in the ratio at 2 
hours when comparing the Veh and APAP groups, no change at 4 hours, and a decrease in the 
APAP treatment group when compared to Veh at 6 hours.  The trend observed in the ratios was 
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due to the SAH levels decreasing 2 hours following APAP administration and steadily increasing 
thereafter.  Decrease of the ratio of SAMe:SAH could inhibit crucial transmethylation reactions.  
Of interest for clinical situations was that the administration of SAMe following APAP overdose 
lead to an increase in liver homogenate SAMe back to control levels.   
Mitochondria are dependent on the presence of SAMe for proper function.  Inhibition of SAMe 
transport into hepatic mitochondria has been demonstrated to sensitize the cells to tumor necrosis 
factor (TNF) hepatotoxicity (Song et al., 2007).  TNF has been shown to be unregulated in 
response to APAP overdose (Dambach et al., 2006).  Also, SAMe has been demonstrated to aid 
in the maintenance of mitochondrial membrane potential in a cell culture model (Lotkova et al., 
2005).  One of the hallmarks of APAP toxicity is mitochondrial dysfunction (Bajt et al., 2008).  
We present here, for the first time, analysis of mitochondrial and 15,000 x g supernatant levels of 
SAMe following APAP overdose.   
The observed decrease in mitochondrial SAMe levels could make mitochondria more susceptible 
to APAP toxicity.  We were also able to establish a time course for the depression of 
mitochondrial SAMe levels occurring between 2 and 4 hours following APAP administration.  A 
spike in cellular SAMe levels was observed in liver homogenate, mitochondria, and 15,000 x g 
supernatant at 2 hours following SAMe administration.  When SAMe was administered 
following APAP, it was able to dramatically increase levels of mitochondrial SAMe at 2, 4, and 
6 hours.  SAMe increased to levels surpassing the control mice indicating that SAMe transport 
into mitochondria is not inhibited by APAP toxicity.  Further studies may provide better insight 
into mitochondrial SAMe transport regulation in response to APAP toxicity.   
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The purpose of SAMe in the cytosol is to function as a methylator and in the synthesis of 
polyamines as well as participating in the transsulfuration pathway to replenish cellular reduced 
glutathione.  At 4 and 6 hours following APAP overdose, the levels of SAMe in the 15,000 x g 
supernatant are depressed when compared to the control mice.  When SAMe was administered 
following APAP it was able to aid in the recovery of SAMe levels to amounts surpassing 
controls at 2 and 4 hours. 
Given the role of SAMe in methylation of DNA, we examined the amount of SAMe present in 
the nuclei of cells treated with APAP.  Caudill et al. (2001) noted that, in cases of SAH 
elevation, DNA trended toward hypomethylation regardless of SAMe levels.  We found that 
levels of SAH were not elevated in the APAP treatment group compared to any other group 
indicating that it would be unlikely for the hepatocytes to experience DNA hypomethylation as a 
result of APAP toxicity even though SAMe levels dropped below the detectable limit of 12.5 
pmol in the APAP treatment groups.     
Expression of MAT I/III is important for the protection of the liver, and its absence can lead to 
unwanted proliferation of hepatocytes (Lu et al., 2001).  These findings have significance 
because the presence of MAT I/III appears to be necessary for the normal function of 
hepatocytes (Lu and Mato, 2008).  Furthermore, SAMe has been found to prevent dysfunction of 
MAT I/III following administration of carbon tetrachloride, a prototypical liver toxicant 
(Corrales et al., 1992).  MAT levels were significantly depressed at 2 and 4 hours following 
APAP administration when compared with the Veh groups.  SAMe levels have been found to fall 
initially following partial hepatectomy; however, expression of MAT1A increases as soon as 3 
hours following partial hepatectomy (Huang et al., 1998).   Our data did not demonstrate the 
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increase in expression of MAT I/III proteins, but we did not look at mRNA expression as did 
Huang and associates.   
Unfortunately, the rise in MAT II expression that typically accompanies liver regeneration was 
not observed by our laboratory at 2 or 4 hours following APAP overdose (Latasa et al., 2001).  
Perhaps future studies monitoring time periods beyond 4 hours following APAP administration 
will yield an appreciable expression of MAT II in APAP treated mice. In a prior study looking at 
MAT II following partial hepatectomy, a rise in the mRNA of MAT2A was observed as soon as 6 
hours following the surgery (Horikawa et al., 1996).  Future studies would also examine mRNA 
levels for MAT II which could yield earlier indications that MAT II was being upregulated.   
Work done on MAT activity concluded that MAT I and MAT II activity are inhibited by SAMe, 
while MAT III is actually activated by SAMe (Sullivan and Hoffman, 1983).  Given that there 
was no expression of MAT II observed at the time periods studied, the activity present comes 
from MAT I/III.  When SAMe was administered either alone or after APAP overdose, activity of 
MAT was significantly decreased when compared with the APAP group at 2 hours.   MAT 
activity was not different between groups 4 hours post APAP treatment.  Given the propensity of 
SAMe to inhibit MAT, the data at 2 hours following APAP administration is easily understood.  
A spike in SAMe levels occurs 2 hours following APAP overdose in liver homogenate which 
could lead to the observed MAT inhibition without a significant change in expression for the 
SAMe or the SAMe administered following APAP group.  By 4 hours the increase in SAMe 
brought about by SAMe administration in liver homogenate samples has largely dissipated 
leading to the return of MAT activity to Veh levels in the SAMe and S + A groups.  Previous 
research found a link between reduced glutathione depletion and decreased MAT activity 
(Corrales et al., 1991).  The same group found that cysteine modification was most likely 
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responsible for the observed decrease in MAT activity (Pajares et al., 1991).  Cellular reduced 
glutathione depletion is a hallmark of APAP toxicity making the current findings interesting in 
the sense that APAP administration did not reduce activity of MAT at 2 or 4 hours (Mitchell et 
al., 1973).  The observed decrease in MAT I/III expression could be because of covalent 
modifications at the antibody binding site and, if so, does not translate to a decrease in MAT 
activity for the time periods studied. 
In conclusion, this is the first study to report a time analysis of SAMe levels in mitochondria, 
15,000 x g supernatant, and the nucleus following APAP overdose.  APAP overdose decreased 
SAMe in whole liver, mitochondria, and 15,000 x g supernatant at 4 and 6 hours, while there is 
no depression of SAMe levels observed at 2 hours.  When SAMe was administered following 
APAP, the levels of SAMe did not decline.  SAMe was not detectable in the nucleus at 2 hours 
following APAP treatment even though our level of sensitivity was 12.5 pmol of SAMe.  We 
have also demonstrated here for the first time that administration of NAC following APAP aided 
in the maintenance of liver homogenate SAMe levels 4 hours after APAP overdose.  At both 2 
and 4 hours following APAP administration, levels of MAT were significantly decreased with 
respect to the Veh group in the APAP treatment group.   MAT activity tended to decrease when 
SAMe was administered and livers collected at 2 hours following APAP overdose, but no 
changes were observed at 4 hours.  These results provide important insight into the effects of 
APAP overdose on SAMe metabolism in C57BL/6 mice and chart a path for future study.   
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Abstract 
Acetaminophen (APAP) overdose leads to severe hepatotoxicity, increased oxidative stress and 
mitochondrial dysfunction.  S-adenosyl-L-methionine (SAMe) protects against APAP toxicity at 
a mmol/kg equivalent dose to N-acetylcysteine (NAC).  SAMe acts as a principal biological 
methyl donor and participates in polyamine synthesis which increase cell growth and has a role 
in mitochondrial protection.  The purpose of the current study tested the hypothesis that SAMe 
protects against APAP toxicity by maintaining critical antioxidant enzymes and markers of 
oxidative stress.  Male C57Bl/6 mice were treated with vehicle (Veh; water 15 ml/kg, ip), SAMe 
(1.25 mmol/kg, ip), APAP (250 mg/kg, ip), and S + A (SAMe given 1 hour following APAP).  
Liver was collected  2 and 4 hours following APAP administration; mitochondrial swelling as 
well as hepatic catalase, glutathione peroxidase (GPx), glutathione reductase, and both Mn- and 
Cu/Zn-superoxide dismutase (SOD) enzyme activity were evaluated.  Mitochondrial protein 
carbonyl, 3-nitrotyrosine cytochrome c leakage were analyzed by Western blot. SAMe 
significantly increased SOD, GPx, and glutathione reductase activity at 4 hours following APAP 
overdose.  SAMe greatly reduced markers of oxidative stress and cytochrome C leakage 
following APAP overdose. Our studies also demonstrate that a 1.25 mmol/kg dose of SAMe 
does not inhibit CYP 2E1 enzyme activity.  The current study identifies a plausible mechanism 
for the decreased oxidative stress observed when SAMe is given following APAP. 
 
KEY WORDS:  S-adenosyl-L-methionine, Acetaminophen, Hepatotoxicity, Oxidative stress, 
Antioxidant, Nitrotyrosine  
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1. Introduction 
Acetaminophen (APAP) is the leading cause of drug induced liver injury. APAP overdose is a 
serious clinical problem resulting in over 26,000 hospitalizations per year in the United States 
(Nourjah et al., 2006).  APAP toxicity results in severe hepatic centrilobular necrosis (Anundi et 
al., 1993).  Currently, N-acetylcysteine (NAC) is the accepted treatment for APAP overdose in 
humans. 
APAP toxicity requires biotransformation  by cytochrome P450 isozymes 2E1, 1A2, and 3A4 of 
APAP to N-acetyl-p-benzoquinoneimine (NAPQI), the ultimate hepatotoxic metabolite (Dahlin 
et al., 1984; Patten et al., 1993; Chen et al., 1998).  Excess NAPQI rapidly depletes cellular 
stores of reduced glutathione (GSH) and subsequently adducts proteins in the liver precipitating 
cellular dysfunction (Hinson et al., 1995).  The current treatment for APAP toxicity, NAC, works 
by replenishing cellular GSH to prevent the cell from being overwhelmed by NAPQI (Smilkstein 
et al., 1988).  Because of the rapid conversion of APAP to NAPQI, prompt administration of 
NAC is critical to improving the clinical outcome; therefore, therapeutic interventions that work 
longer term to combat APAP toxicity are desirable.   
APAP hepatotoxicity is characterized by greatly increased oxidative stress due to mitochondrial 
dysfunction and the generation of superoxide (Andersson et al., 1990).  A common indicator of 
oxidative stress is lipid peroxidation, which has been found to be greatly increased in response to 
APAP toxicity (Wendel et al., 1979).  In addition to the generation of reactive oxygen species 
(ROS), APAP also causes the production of reactive nitrogen species (RNS) leading to 
nitrotyrosine adduction of proteins (Hinson et al., 2000).  Histology indicates that nitrotyrosine 
adduction is localized to the centrilobular region where APAP toxicity is most prevalent. 
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A key defense modulating the severity of APAP hepatotoxicity are the antioxidant enzymes 
glutathione reductase (GSSG reductase), glutathione peroxidase (GPx), catalase, and superoxide 
dismutase (SOD).  APAP toxicity has previously been demonstrated to reduce antioxidant 
enzyme activities and a few exogenous treatments have been tested to restore enzymatic function 
(Olaleye et al., 2008; Wu et al., 2010).  NAC has also been demonstrated to protect the function 
of GPx and SOD when administered 2 hours prior to APAP overdose (300 mg/kg body weight) 
(Wang et al., 2010).  An endogenously produced molecule, such as S-adenosyl-L-methionine 
(SAMe), with the same protective benefits could prove a beneficial therapeutic compound.   
Mitochondrial dysfunction is another hallmark of APAP toxicity and a contributing factor to the 
greatly increased oxidative stress observed with APAP overdose.  Masubuchi and others 
determined that APAP injury induces mitochondrial permeability transition (MPT) in mice 
which is characterized by the loss of membrane potential and cellular ATP depletion (Masubuchi 
et al., 2005).  MPT is also associated with the exodus of proteins from the mitochondrial inner 
membrane such as cytochrome c which has a role in initiating apoptosis (El-Hassan et al., 2003).  
ATP depletion occurs with APAP toxicity and acts as a precursor to the necrotic damage by 
inhibiting completion of apoptosis (Jaeschke and Bajt, 2006).   
Prior research by our laboratory has demonstrated the ability of S-adenosyl-L-methionine 
(SAMe) to protect against APAP toxicity at a mmol/kg dose comparable to NAC (Terneus et al., 
2007 and 2008).  Humans produce 6-8 g per day of SAMe which is necessary for methylation of 
cellular proteins, DNA, and phospholipids.  In addition to transmethylation reactions, SAMe also 
participates in the transsulfuration pathway to aid in the replenishment of GSH (Lu, 2000).  
SAMe is known to participate in polyamine synthesis which has a critical role in enhancing liver 
regeneration following partial hepatectomy (Fernandez et al., 2003; Brosnan and Brosnan, 2006).  
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Polyamine synthesis and the ability to aid in liver regeneration are both unique properties that 
SAMe possesses over NAC as a potential therapeutic intervention.  SAMe has already been 
recognized to protect mitochondria from alcohol-induced dysfunction (Bailey et al., 2006; Song 
et al., 2007).  Additionally, our laboratory has previously demonstrated SAMe’s ability to reduce 
oxidative stress markers such as the formation of protein carbonyls associated with APAP 
hepatic toxicity (Terneus et al., 2008).   
Given SAMe’s proven ability to protect against APAP toxicity, the current study sought to 
deepen the understanding of the mechanism of SAMe protection.  First, subcellular protection by 
SAMe for APAP hepatic damage within the mitochondria and cytosol is not known. Second, 
information is lacking on the temporal protection of antioxidant enzyme activity by SAMe 
following exposure to APAP overdose.  If protection of antioxidant enzyme activity by SAMe is 
minimal or  only occurs after hepatic damage is manifested, then maintaining antioxidant 
enzyme activity is not a primary mechanism for SAMe protection of APAP hepatic toxicity.  
Additionally, protein carbonyl formation and nitrotyrosine adduction were analyzed on 
mitochondrial samples to determine levels of oxidative stress at a mitochondrial level with 
SAMe treatment after APAP overdose.   
2. Methods and Materials 
2.1 Reagents. SAMe toluene sulfonate salt was used for the experiments and was purchased 
from Sigma-Aldrich  Chemical Company (St. Louis, MO).  All other chemicals were purchased 
from Sigma-Aldrich  Chemical Company (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).   
The SOD Assay kit was purchased from Sigma Chemical Company (19160; St. Louis, MO).  
The OxyBlot
TM
 Protein Oxidation Detection Kit purchased from Millipore (S7150; Temecula, 
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CA).  Alanine aminotransferase (ALT) was assayed using a method based on the discontinued 
Sigma 505-P kit as described by Patel and associates (2011). 
2.2 Animals. Male C57BL/6 mice were obtained from Hilltop Lab Animals Inc. (Scottsdale, 
PA).  Animals included in the study were between 4-8 weeks of age and weighed 16-24 g.  Mice 
were maintained in an American Association for Accreditation of Laboratory Animal Care 
(AAALAC) accredited facility.  Mice were maintained at controlled temperature (21-23°C), 
humidity (40-55%), and 12 hour light cycles (lights on 6:00 AM to 6:00PM).  An acclimation 
period of 7 days was observed prior to the beginning of any experiment.  The animals received 
Purina rodent chow and water ad libitum.  The mice were fasted for 16 hours prior to any 
experiment, but were provided  free access to water. 
2.3 SAMe Treatment Following APAP Overdose. Mice were randomly allocated into the 
following groups:  Vehicle (Veh; 15 mL/kg water by intraperitoneal (ip) injection), SAMe (1.25 
mmol/kg 5mL/kg ip injection), APAP (250 mg/kg 15mL/kg ip injection), and SAMe 
administered 1 hour after APAP (S + A; doses same as previously listed).   SAMe was 
administered 1 hour following APAP.  Mice were anesthetized with carbon dioxide 2 and 4 hour 
after APAP administration.  Blood was collected by cardiac puncture in heparin-rinsed 1 mL 
syringes for determination of plasma ALT activity, which serves as an indicator of liver injury.  
Livers were then isolated and placed in ice cold Kreb’s buffer (126 mM NaCl, 5 mM KCl, 3 mM 
MgSO4, 3 mM Na2HPO4, 1 mM CaCl2; pH 7.4), blotted, and weighed. 
2.4 Mitochondrial Isolation. Mitochondria were isolated using a modification of a previously 
published protocol by Gogvadze and colleagues (2006).  Briefly, the liver was isolated, blotted, 
weighed and placed in Mitochondrial Isolation Buffer A (225 mM sucrose, 3 mM KH2PO4, 5 
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mM MgCl2, 20 mM KCl, 20 mM triethanolamine, 2 mM EGTA; pH 7.4).  The liver was minced 
and homogenized in a Dounce homogenizer on ice.  Following homogenization, the liver was 
centrifuged at 600 x g for 10 minutes.  The resultant pellet was discarded and the supernatant 
was centrifuged at 15,000 x g for 5 minutes.  After the final centrifugation, the supernatant was 
retained for analysis of cytosolic SAMe levels.  The pellet containing the mitochondria was 
resuspended in Mitochondrial Isolation Buffer B (Same as Buffer A except lacking EGTA) for a 
final concentration of 1 mg tissue weight/µL Buffer B.  Samples were stored at -80°C until 
analysis. 
2.5 Catalase Activity Assay. The protocol for determination of catalase activity was based on a 
paper by Zhang and coworkers (2004).  Briefly, tissue was homogenized in Kreb’s buffer (10 
mL/g tissue) and centrifuged at 1000 x g for 15 minutes retaining the supernatant.  For the assay, 
the disappearance of 15 mM H2O2 was measured at 240 nm and the change in absorbance was 
recorded over 1 minute.  The level of catalase was calculated with the extinction coefficient 
(43.6 M
-1
 cm
-1
). 
2.6 GPx Activity Assay. Lawrence and Burk (1976)  developed a protocol which was employed 
to determine hepatic GPx activity.  Liver tissue (100 mg) was homogenized in 1 mL of 
phosphate buffer (50 mM KH2PO4, 1 mM sodium azide, 1 mM EDTA; pH 7.2).  The reaction 
mixture consisted of 0.5 mL phosphate buffer, 0.1 mL 2 mM NADPH, 0.1 mL glutathione 
reductase (1 Unit), 0.1 mL 10 mM reduced glutathione, and 0.1 mL sample.  The reaction was 
initiated with the addition of H2O2 at a final concentration of 0.25 mM and disappearance of 
NADPH was measured for 1 minute at 340 nm.  Activity was calculated using the extinction 
coefficient for NADPH (6.22 x 10
3
 M
-1
 cm
-1
).   
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2.7 GSSG Reductase Activity Assay. GSSG reductase activity was determined based on a 
protocol developed by Mannervik with modifications (1999).  Briefly, 100 mg of liver was 
homogenized in Kreb’s buffer (10 mL/g tissue) and centrifuged 15 minutes at 1000 x g.  50 µL 
of sample was added to a test tube containing 2.7 mL phosphate buffer (120 mM KH2PO4; pH 
7.2), 0.1 mL 15 mM EDTA, and 0.05 mL 65.3 mM glutathione disulfide.  The reaction was 
initiated by the addition of 0.05 mL 10 mM NADPH.  Consumption of NADPH was monitored 
for 1 minute at 340 nm.  A standard curve of known quantities of GSSG reductase was 
constructed for calculations. 
2.8 SOD Activity Assay. SOD activity was determined using a Fluka designed 
spectrophotometric kit purchased from Sigma Chemical Company (19160; St. Louis, MO).  
Cu/Zn-SOD was inhibited by incubating the sample at room temperature sodium 
diethyldithiocarbamate (DDTC) at a final concentration of 25 mM.  The assay was completed 
according to manufacturer’s recommendations. 
2.9 Mitochondrial Swelling Assay. Mitochondrial swelling was determined by a turbidometric 
technique (Gogvadze et al., 2006).  Mitochondrial suspension containing 1 mg protein was set to 
constant spinning in 2 mL incubation buffer (150 mM KCl, 0.5 mM KH2PO4, 5 mM Tris Base, 
100 mM succinic acid; pH 7.4).  Subsequently, 2 µL 2.5 mM rotenone, 5.5 µL 10 mM CaCl2, 
and 20 µL 0.5 M KH2PO4 were added at one minute intervals to initiate the reaction which was 
monitored at 540 nm for 5 minutes recording absorbance every 15 seconds.   
2.10 Western Blotting. Western blot analysis was conducted to examine expression of 
mitochondrial and cytosolic cytochrome c and mitochondrial 3-nitrotyrosine (3-NT) protein 
adduction.  A 100 µg protein aliquot was denatured by boiling for 5 minutes.  Samples were 
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separated on a 12.5% polyacrylamide gel and transferred to a NC membrane (Whatman; Dassel, 
Germany).  Transfer efficiency was verified using MemCode® Reversible Protein Stain Kit 
(Thermo Scientific; Rockford, IL).  The membrane was then blocked using a 5% (w/v) 
milk/TBST solution (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) for 1 hour.  
Membranes were next incubated overnight with constant shaking at 4°C in antibody for 
cytochrome c (sc-7159, Santa Cruz Biotechnology; Santa Cruz, CA) or 3-NT (ab61392, Abcam; 
Cambridge, MA) in 5% (w/v) milk/TBST.  The membranes were washed four times with TBST.   
Appropriate secondary antibodies were incubated with the membranes for 1 hour.  The 
membrane was again washed with TBST and developed using Amersham
TM
 ECL
TM
 Western 
Blotting Detection Reagents (GE Healthcare; Buckinghamnshire, UK).  Densitometry was 
performed on each gel (n = 3-5 mice/group).  
2.11 OxyBlot Analysis. Mitochondrial protein oxidation was assessed using an OxyBlot
TM
 kit.  
The manufacturer’s instructions were followed and 20 µg of protein was derivatized for each 
sample.  Protein loaded was confirmed by MemCode® Reversible Protein Stain staining as in 
the Western blot protocol and results were quantified by densitometry (n = 3-5 mice/group).   
2.12 Cyp 2E1Enzyme Activity and expression. In vitro hepatic biotransformation of aniline to p-
aminophenol (PAP) was used as an indicator of CYP2E1 hepatic enzyme activity. These 
experiments were conducted in order to evaluate whether SAMe inhibited P450 mediated APAP 
metabolism. Microsomes were isolated from livers 2 and 4 hour post APAP treatment using the 
methods of Schlenkman and Jansson (1999). Aniline para-hydroxylation to PAP was measured 
as described previously (Valentovic et al., 1988). Values were reported as nmol/mg protein/20 
minute incubation.   
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2.13 Statistical Analysis. Values represent Mean ± S.E.M. with n=3-5 animals/group.  
Differences in the groups were analyzed using a one-way ANOVA followed by a Tukey’s post-
hoc test (SigmaStat; SPSS Inc. Chicago, IL).  All statistical analyses were conducted using a 
95% confidence interval.   
3. Results 
3.1 SAMe Attenuation of Hepatic APAP toxicity. Body weights were similar  between all 
treatment groups (Table 8).  Liver weight/10 g body weight were increased 2 and 4 hours after  
APAP treatment relative to the Veh mice.  Plasma ALT levels were significantly increased 2 and 
4 hours (p<0.05) in the APAP group confirming APAP overdose (Figure 13).  SAMe partially 
protected the liver from APAP toxicity as indicated by a less marked increase in ALT levels 
compared to the APAP group. ALT values were 80% lower in the S + A group compared to the 
APAP mice.  SAMe afforded partial correction as ALT values were still higher than Veh ALT at 
either the 2 or 4 hour time period.  The ALT measurement indicates that SAMe administered 1 
hour after APAP reduced hepatic toxicity. 
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Table 8.  Comparison of liver and body weight following APAP administration in C57Bl/6 
mice 
 
Value are mean ± S.E.M. with n=5 animals per group. 
 
a, b, c, ab 
Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results. 
 
 
- 91 - 
 
 
Figure 13.  ALT levels in blood plasma 2 and 4 hours following APAP administration to 
C57Bl/6 mice.  Mice were randomly allocated into Veh (water), SAMe (1.25 mmol/kg), APAP 
(250 mg/kg), and SAMe administered 1 hour following APAP (S + A).  Values represent mean ± 
S.E.M. with n=5 mice per group. Different letters denote statistical differences (p<0.05), while 
groups with the same letters indicate no difference in the results. 
  
3.2 Antioxidant Enzyme Activity protection by SAMe.  Relative to the Veh group, SAMe did not 
alter catalase or GPx enzyme activity (Figures 14 & 15).  Catalase activity was similar for all 
groups at the 2 hour time period but  at 4 hours, APAP diminished catalase enzyme activity over 
30%  when compared to Veh and SAMe groups (p<0.05).  The S + A group did not show 
significant elevations in catalase activity compared with the APAP group, but there was a trend 
toward improvement.  APAP depressed GPx activity at both the 2 and 4 hour (p<0.05) time 
periods when compared to the Veh and SAMe groups (Figure 15).  GPx was diminished at 2 
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hours in the S + A group compared to the Veh and SAMe groups but activity was partially 
restored at 4 hours in the S + A group.  SAMe did not totally reverse the effects of APAP as GPx 
activity in the S + A group were higher than the APAP group but still lower than the Veh and 
SAMe groups at 4 hours (p<0.05).     
 
Figure 14.  Catalase enzymatic activity in the liver 2 and 4 hours following APAP overdose in 
C57Bl/6 mice was assessed with mice randomly divided into Veh (water), SAMe (1.25 
mmol/kg), APAP (250 mg/kg), and SAMe administered 1 hour post-APAP (S + A).  Values 
represent mean ± S.E.M. with n=5 mice per group. Different letters denote statistical differences 
(p<0.05), while groups with the same letters indicate no difference in the results.  
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Figure 15.  Liver GPx activity alterations when SAMe was administered 1 hour after APAP 
overdose.  C57Bl/6 mice were randomly divided into Veh (water), SAMe (1.25 mmol/kg), 
APAP (250 mg/kg), and SAMe administered 1 hour following APAP (S + A).  Livers were 
collected 2 and 4 hours following APAP overdose.  All values represent mean ± S.E.M.  
Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results. 
 
SAMe treatment did not alter GSSG reductase enzyme activity at either the 2 or 4 hour time 
periods when compared to Veh (Figure 16).  APAP treatment depressed GSSG reductase activity 
(p<0.05) by 36% and 42% of Veh levels, at the 2 and 4 hour time periods, respectively.  GSSG 
reductase activity at 2 hours in the S + A treatment group was similar to the APAP and SAMe 
levels.  However, at 4 hours S + A had returned GSSG reductase activity to levels comparable to 
Veh and SAMe activity. 
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Figure 16.  GSSG reductase activity in the liver following APAP overdose in C57Bl/6 mice was 
determined by enzymatic assay.  Mice were randomly allocated into Veh (water), SAMe (1.25 
mmol/kg), APAP (250 mg/kg), and SAMe administered 1 hour following APAP (S + A) and 
livers collected 2 and 4 hours following APAP overdose.  Each group represents 5 experiments 
with different mice. Different letters denote statistical differences (p<0.05), while groups with 
the same letters indicate no difference in the results. SOD activity was measured for 2 and 4 hour 
treatment groups and expressed as total, cytosolic (Cu/Zn-SOD), and mitochondrial (Mn-SOD).  
SAMe treatment did not alter total, Cu/Zn, and Mn-SOD at any time period examined (Figure 
17).  In the 2 hour treatment group, total SOD and Mn-SOD activity were lower (p<0.05) in the 
S + A group compared to the Veh and SAMe mice.  The Veh, SAMe, and APAP groups showed 
no significant difference (Figure 17, Panel A) for any form of SOD at 2 hours.  The Veh group 
did not differ significantly from the S + A group for Cu/Zn-SOD.  Mn-SOD was significantly 
decreased (p<0.05) in the S + A group when compared to the Veh and SAMe groups at 2 hours, 
and no difference was observed when compared to the APAP treatment group.   
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Figure 17.  SOD activity following APAP overdose in C57Bl/6 mice.  Cu/Zn-SOD was inhibited 
with DDTC for determination of Mn-SOD.  Panel A represents SOD levels 2 hours following 
APAP overdose, while panel B represents SOD levels 4 hours following APAP overdose.  
Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results. 
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In the 4 hour treatment groups, total, Cu/Zn, and Mn-SOD activities were decreased (p<0.05) in 
the APAP group when compared with the Veh and SAMe groups (Figure 17, Panel B).  It 
appeared that a longer time period of 4 hours was needed to produce a decline in SOD activity.  
Treatment with SAMe (S + A) increased total and Cu/Zn-SOD activity to levels similar to Veh 
and SAMe.  The 4 hour Mn-SOD activity in the S + A group was not significantly different from 
the APAP group. 
3.3 SAMe attenuates mitochondrial APAP induced Protein Carbonyl and 3-Nitrotyrosine 
adduction. As a global measure of the effect of SAMe’s ability to reduce mitochondrial 
oxidative stress, OxyBlots were performed on mitochondrial samples to detect protein carbonyl 
formation.  In both 2 and 4 hour samples, densitometry was significantly increased (p<0.05) in 
the APAP treatment groups when compared to the Veh and SAMe groups (Figure 18).  When 
SAMe was administered following APAP, the density returned to be comparable to the Veh and 
SAMe treatment groups indicating that SAMe treatment lessens the formation of protein 
carbonyls in the mitochondria of APAP treated C57Bl/6 mice.  These results are consistent with 
the protection observed by S + A for the antioxidant enzyme activities (Figures 14-17). 
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Figure 18.  Protein carbonyl formation in C57Bl/6 mouse mitochondria 2 and 4 hours following 
APAP overdose.  Protein carbonyls were assessed using an OxyBlot
TM
 kit.  Panel A contains 
densitometry from 2 and 4 hour OxyBlots
TM
 following APAP overdose.  Densitometry was 
normalized to total protein staining (not shown) and is expressed as % Veh.  All values represent 
mean ± S.E.M. with n=4 mice per group.  Different letters denote statistical differences (p<0.05), 
while groups with the same letters indicate no difference in the results. Panel B is a 
representative 4 hour blot with lanes 1-2 corresponding to Veh, 3-4 SAMe, 5-6 APAP, and 7-8 
SAMe administered 1 hour following APAP (S + A). 
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APAP significantly increased mitochondrial 3-NT protein adduction 4 hours following overdose 
when compared to Veh and SAMe treatment groups (Figure 19).  SAMe decreased the amount of 
mitochondrial 3-NT adduction when administered following APAP.  Even though there was a 
similar increase in mitochondrial 3-NT adduction in the 2 hour group, SAMe was less effective 
at decreasing the amount of adduction observed at this time period (data not shown).   
 
Figure 19.  Mitochondrial 3-NT protein formation 4 hours following APAP overdose.  Panel A 
is a representative 4 hour blot containing mitochondrial samples from the indicated groups.  
Panel B is the densitometry from panel A for whole lane 3-NT adduction normalized to total lane 
protein staining.  Protein staining such as that presented in Panel C was used to normalize protein 
levels.  Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  Values are mean ± S.E.M. with n=3-5 mice per group.   
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3.4 Cytochrome c release. Mitochondrial function was also analyzed by examining 
mitochondrial swelling following APAP overdose.  There was a significant increase in 
mitochondrial swelling at both 2 and 4 hours following APAP overdose (Figure 20, Panels A and 
B).  SAMe was not able to prevent the increased swelling observed during these time periods, 
and there was not a significant difference observed between the APAP and S + A groups except 
in the 4 hour treatment group 1 minute after swelling was induced when the S + A group was 
significantly lower than the APAP group.   
Cytochrome c leakage was used to assess mitochondrial function associated with APAP toxicity.  
Cytochrome c leakage into the cytosol was 20% greater in the APAP group when compared with 
the Veh group 2 and 4 hours following APAP overdose, although the results were not significant 
at the 2 hour time period (Figure 20, Panel C).  SAMe was able to prevent the release of 
cytochrome c into the cytosol at 4 hours when compared to the APAP group.  The increased 
cytosolic cytochrome c is also evident in a representative blot included in Figure 20, Panel D. 
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Figure 20.  Mitochondrial swelling and cytochrome c leakage were used to assess mitochondrial 
function following APAP overdose.  Mice were randomly allocated into Veh (water), SAMe 
(1.25 mmol/kg), APAP (250 mg/kg), and SAMe administered 1 hour following APAP.  Livers 
were collected 2 and 4 hours following APAP administration and analyzed for mitochondrial 
swelling (Panel A and B).  Panel C represents densitometry conducted on cytosolic cytochrome c 
levels following APAP overdose when analyzed at 2 and 4 hours.  Panel D is a representative 4 
hour cytosol cytochrome c blot depicting Veh (Lanes 1 and 2), SAMe (Lanes 3 and 4), APAP 
(Lanes 5 and 6), and S + A (Lanes 7 and 8).  All values represent mean ± S.E.M. with at least 4 
mice represented in each group.  Different letters denote statistical differences (p<0.05), while 
groups with the same letters indicate no difference in the results. 
 
 
 
 
- 101 - 
 
3.5 CYP 2E1 enzyme activity and expression. Aniline para-hydroxylation to PAP was used as an 
indicator of CYP2E1 enzyme activity. SAMe treatment, at the dose used in this study, did not 
alter aniline hydroxylation. APAP diminished CYP2E1 enzyme activity at 2 and 4 hours relative 
to the Veh and SAMe groups (Figure 21). The S + A group  had higher enzyme activity than the 
APAP group at 2 hours but PAP formation  was slower than the Veh and SAMe groups at 2 
hours. Enzyme activity was similar to Veh and SAMe at 4 hours. These results indicate that the 
mechanism for protection by SAMe is not due to inhibition of P450 metabolism at the dose used 
in our studies. Western analysis of protein expression also showed that SAMe does not alter 
CYP2E1 enzyme expression at 2 or 4 hours. APAP diminished CYP 2E1 expression at 2 and 4 
hours compared to all other groups.  
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Figure 21. CYP2E1 enzyme activity and expression in APAP treated mice. Panel A represent 
densitometry for CYP2E1 enzyme expression measured at  2 hours  (Panel B)  and 4 hours 
(Panel C) using a Western blot. APAP inhibited CYP2E1 expression while SAMe did not inhibit 
CYP2E1 expression. Panel D represent para-hydroxylation of aniline to p-aminophenol (PAP) 
measured 2 and 4 hours after APAP treatment in groups as described in Fig. 1. Enzyme activity 
was expressed as nmol PAP/mg protein/20 minutes. All values represent mean ± S.E.M. with at 
least 4 mice represented in each group.  Superscripts denote statistical differences between 
groups (p<0.05). 
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4.  Discussion 
Our laboratory has previously reported that SAMe reduced  APAP toxicity in C57Bl/6 mice 
when administered 0 or 1 hours after APAP (Terneus et al., 2007 & 2008).  SAMe can reduce 
protein carbonylation and lipid peroxidation when administered after a toxic dose of APAP.  
Previous work established the importance of ROS and RNS generation in APAP toxicity (Cover 
et al., 2005).  Damage caused by ROS and RNS is thought to be preceded by NAPQI induced 
GSH depletion, which we have previously demonstrated the ability of SAMe to prevent in APAP 
treated mice.  However, the current study shows that SAMe also has the potential to protect the 
function of critical antioxidant enzymes normally altered by APAP toxicity.   
SOD has been extensively studied with APAP toxicity.  Decreased levels of Mn-SOD have been 
shown to significantly increase APAP toxicity, which is consistent with the generation of 
superoxide occurring primarily in the mitochondria with APAP toxicity (Yoshikawa et al., 2009; 
Ramachandran et al., 2011).  Furthermore, Mn-SOD activity has recently been demonstrated to 
be decreased with nitration secondary to APAP toxicity (Agarwal et al., 2011).  At 4 hours, 
SAMe given 1 hour after APAP (S + A group) decreased 3-NT adducts globally in mitochondrial 
protein which is consistent with the observed correction  in Mn-SOD activity observed for the S 
+ A group compared to APAP. The exact mechanism for SAMe decreasing APAP mediated 
nitration of tyrosine residues in proteins is not known. However, these results suggest SAMe 
interferes with APAP induced mitochondrial dysfunction and oxidative stress.      
In contrast to decreased expression of Mn-SOD, Cu/Zn-SOD knockout mice show almost 
complete protection against APAP overdose (Zhu et al., 2006).  SAMe given as an antidote to 
APAP toxicity clearly protects total SOD activity 4 hours following APAP with significant 
increases in Cu/Zn-SOD activity and improvement.  We clearly observed protection when SAMe 
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was given following APAP indicating that, in our model, the modest increase in Mn-SOD may 
be of greater importance than the increase in Cu/Zn-SOD. In addition, full function of all 
antioxidant enzymes is important in reducing oxidative stress as hydrogen peroxide formed from 
Mn-SOD and Cu/Zn-SOD is also toxic and is detoxified by catalase and glutathione peroxidase.  
Evidence has existed for some time that the GPx-GSSG reductase system was protective in cases 
of APAP toxicity (Adamson et al., 1989).  However, it is also apparent that over expression of 
intracellular GPx can increase APAP toxicity most likely as a result of enhanced GSH depletion 
(Mirochnitchenko et al., 1999).  Our results clearly demonstrated a depression of GPx activity 2 
and 4 hours following APAP overdose, which was reversed at 4 hours by SAMe administration.  
The fact that GPx activity was not returned to Veh level may be beneficial in light of the study 
on GPx over expression increasing APAP toxicity.  Additionally, the increased activity of GSSG 
reductase at 4 hours in the S + A group would serve to increase cellular levels of GSH and 
decrease glutathione disulfide levels, which is consistent with prior results from our laboratory 
(Terneus et al., 2007 and 2008). 
Catalase represents an important link in the detoxification of ROS generated as a result of APAP 
toxicity because it does not require GSH to function.  Clear evidence exists that APAP can 
depress catalase activity at 6 and 24 hours following APAP administration (Yan et al., 2009; 
Chandrasekaran et al., 2011).  Additionally, antioxidant administration prevents the observed 
decrease in catalase activity.  SAMe does not have antioxidant properties and was still able to 
improve catalase function, although not significantly, 4 hours following APAP administration.  
Formation of the reactive metabolite NAPQI has long been known to be a prerequisite for 
mitochondrial dysfunction associated with APAP toxicity (Weis et al., 1992).  More recent work 
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suggests that the observed changes in mitochondrial function are caused by JNK activation 
following both GSH depletion and resultant oxidative stress (Saito et al., 2010).  Additionally, 
peroxynitrite formation has been demonstrated to increase fragmentation of mitochondrial DNA, 
which could be a cause of some of the observed mitochondrial dysfunction (Cover et al., 2005).  
We demonstrated a clear reduction in markers of oxidative stress when SAMe was given after 
APAP in the 4 hour treatment group.  Additionally, the reduction in mitochondrial 3-NT adduct 
formation at 4 hours with SAMe administration could be beneficial to function following APAP 
overdose.   
Cytochrome c has previously been used as a marker for APAP toxicity (Song et al., 2004).  
However, it is clear that APAP toxicity is a necrotic event and caspase activation associated with 
apoptosis is abrogated by ATP depletion associated with toxicity (Kon et al., 2004).  SAMe 
prevents release of cytochrome c into cell cytosol at both 2 and 4 hours following APAP toxicity 
indicating mitochondrial protection. The dose of APAP used in our studies induced necrosis as 
the percent release of cytochrome c into cytosol was less than 30% of total cytochrome c. 
One finding of interest was that SAMe did not prevent mitochondrial swelling when 
administered following APAP overdose.  This finding contradicts the work of Song and 
associates (2004)  which clearly demonstrated SAMe decreased mitochondrial swelling when 
given as an antidote to APAP toxicity.  Three factors may account for the difference in findings 
between the current and previous study.  First, our laboratory used a much higher concentration 
of calcium to initiate swelling in combination with additional phosphate and rotenone, which 
were not used in the Song research.  Waldmeier and others demonstrated that even a high 
concentration of cyclosporine A cannot indefinitely inhibit permeability transition when isolated 
mitochondria are exposed to high concentrations of both calcium and phosphate (Waldmeier et 
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al, 2009).  Second, the concentration of SAMe used by Song et al. (2004) was double that used 
by our laboratory in the current experiment.  Perhaps SAMe needs to be present at a higher level 
than was used in the current experiment to provide protection against APAP induced 
mitochondrial swelling.  Additionally, APAP (200 mg/kg, ip) has been demonstrated to undergo 
rapid conversion to NAPQI depleting cellular glutathione within 20 minutes of administration 
(Bajt et al., 2011).  The current protocol administered SAMe 1 hour after APAP, allowing more 
than enough time for NAPQI to form and cause some damage that could weaken the 
mitochondria, rendering them more susceptible to swelling.  However, given the bulk of the data 
presented in this paper, SAMe is providing clear protection following APAP overdose.   
Biotransformation of APAP by cytochrome P450 is critical for formation of NAPQI and 
development of hepatotoxicity (Patten et al., 1993; Chen et al., 1998). Caro and Cederbaum 
(2005) reported that SAMe inhibited in vitro CYP2E1 metabolism in rat microsomes and in 
HepG2 cells. The IC50 was reported as 1.5 mM for CYP2E1. In our studies, inhibition of 
CYP2E1 by SAMe is not the mechanism for reduced hepatic APAP  toxicity in vivo when we 
administered SAMe 1 hour after APAP. In our study we administer a dose of 1.25 mmol/kg 
SAMe which corresponds to approximately 30 µmoles distributed within the entire animal. The 
low amount administered to the animal is not sufficient to inhibit P450 enzyme activity. 
However, we also measured in vitro CYP2E1 metabolism and expression (Figure 21) which 
confirms P450 metabolism is not inhibited by SAMe.  
In conclusion, we present here a clear line of evidence that the observed decrease in oxidative 
stress mediated by SAMe is in part due to the maintenance of antioxidant enzyme function 
following APAP overdose.  Antioxidant enzyme function is greatly improved 4 hours following 
APAP overdose when SAMe is given as an antidote.  Also, cytochrome c release is inhibited by 
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SAMe 4 hours following APAP, indicating a protection of mitochondrial function.  
Mitochondrial dysfunction due to oxidative stress and resultant ATP depletion are critical factors 
in APAP toxicity.  By protecting against mitochondrial oxidative stress, SAMe provides a 
potentially useful therapeutic intervention following APAP toxicity.  
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Abstract 
Acetaminophen (APAP) causes severe centrilobular necrosis in cases of overdose leading to 
about 45,000 emergency room visits annually.  Our laboratory has previously found good 
protection against APAP overdose by S-adenosyl-L-methionine (SAMe).  In order to gain a 
better mechanistic understanding of how SAMe protects against APAP toxicity, we analyzed 
mitochondrial protein adduction by the reactive lipid intermediate 4-hydroxy-2-nonenal (4-HNE) 
as well as methionine S-oxidation.  Additionally, we analyzed levels of the polyamines 
spermidine (Spd) and spermine (Spm) following APAP overdose since SAMe is essential for 
their synthesis.  Each experiment consisted of 20 mice divided into:  Veh (15 ml/kg water, ip), 
SAMe (1.25 mmol/kg, ip), APAP (250 mg/kg), and SAMe given one hour after APAP.  We 
found 4-HNE adduction of several proteins including aldehyde dehydrogenase and carbamoyl 
phosphate synthase-1 (CPS-1) using proteomic analysis.  We confirmed CPS-1 adduction with 
Western blotting.  SAMe also protected levels of the polyamines Spd and Spm following 
overdose with APAP.  The current work leads to a better understanding of the mechanism by 
which SAMe is able to prevent APAP toxicity. 
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Introduction 
Acetaminophen (APAP) is a well-recognized and widely studied hepatotoxicant.  APAP toxicity 
is clinically relevant as it is the number one cause of drug induced liver failure (Manthripragada 
et al., 2011). Post-translational modifications of proteins have been identified with many toxins 
including APAP. This drug can induce covalent binding by generation of a toxic P450-derived 
intermediate, NAPQI (Zhou et al., 1996). APAP can further induce oxidative stress resulting in a 
series of events that can generate reactive oxygen and nitrogen species, products recognized to 
induce covalent modifications of proteins (Knight et al., 2001).  
The purpose of this study was to determine post-translational modification of proteins following 
APAP treatment in a mouse model. We first evaluated protein carbonyl generation in liver 
following APAP treatment and the reduction in protein carbonyl formation by treatment with 
SAMe. Studies conducted by the University of Arizona research group under the direction of Dr. 
Serrine Lau then evaluated 4-hydroxynonenal (4-HNE) adduction of liver proteins. Further 
studies by our laboratory then examined leakage of mitochondrial proteins into the cytosol as 
markers of damage and the protection afforded by SAMe. Finally, we examined whether APAP 
alters hepatic polyamine pathway products spermine and spermidine and whether SAMe 
preserves the polyamine pathway in APAP treated mice.  
 
Methods  
Materials:  SAMe toluene sulfonate salt was used for the experiment and was purchased from 
Sigma Chemical Company (St. Louis, MO).  All other chemicals were purchased from Sigma 
Chemical Company or Fisher Scientific (Pittsburgh, PA).  Alanine aminotransferase (ALT) was 
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assayed using a method based on the discontinued Sigma 505-P kit described by the Harvison 
laboratory (Patel et al., 2011). 
Animals:  Male C57Bl/6 mice were obtained from Hilltop Lab Animals Inc.  (Scottsdale, PA) 
and were between 4-8 weeks of age weighing 18-24 g at the time of the experiment.  Mice were 
fasted for 16 hours prior to the experiment. 
Treatment Groups:  Mice were randomly allocated into the following groups:  vehicle (Veh; 15 
ml/kg water, ip inj), SAMe (1.25 mmol/kg 5 ml/kg, ip inj), APAP (250 mg/kg 15 ml/kg, ip inj), 
and SAMe given 1 hour following APAP (S+A; S + A).  Mice were anesthetized with carbon 
dioxide 4 hours after APAP administration.  Blood was collected by cardiac puncture in heparin-
rinsed 1 mL syringes for determination of plasma ALT activity.  Mitochondria and cytosolic 
fractions were then obtained for Western blotting. 
Mitochondrial Isolation:  Mitochondria were isolated using a modification of a previously 
published protocol by Gogvadze and colleagues (2006).  Briefly, the liver was isolated, blotted, 
weighed and placed in Mitochondrial Isolation Buffer A (225 mM sucrose, 3 mM KH2PO4, 5 
mM MgCl2, 20 mM KCl, 20 mM triethanolamine, 2 mM EGTA; pH 7.4).  The liver was minced 
and homogenized in a Dounce homogenizer on ice.  Following homogenization, the liver was 
centrifuged at 600 x g for 10 minutes.  The resultant pellet was discarded and the supernatant 
was centrifuged at 15,000 x g for 5 minutes.  After the final centrifugation, the supernatant was 
retained for analysis of cytosolic SAMe levels.  The pellet containing the mitochondria was 
resuspended in Mitochondrial Isolation Buffer B (Same as Buffer A except lacking EGTA) for a 
final concentration of 1 mg tissue weight/1 ml Buffer B.  Samples were stored at -80°C until 
analysis. 
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Western Blotting:  Western blot analysis was conducted to examine expression of CPS-1 and 
then stripped and reprobed with 4-HNE to confirm adduction.  A 100 µg cytosolic protein 
aliquot was denatured by boiling for 5 minutes.  Samples were separated on a 12.5% 
polyacrylamide gel and transferred to a nitrocellulose (NC) membrane (Whatman; Dassel, 
Germany).  Transfer efficiency was verified using MemCode® Reversible Protein Stain Kit 
(Thermo Scientific; Rockford, IL).  The membrane was then blocked using a 5% (w/v) 
milk/TBST solution (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) for 1 hour.  
Membranes were next incubated overnight with constant shaking at 4°C in antibody for CPS-1 
(sc-10515; Santa Cruz Biotechnology; Santa Cruz, CA) at a 1:200 dilution in 5% (w/v) 
milk/TBST.  The membranes were washed four times with TBST.  The donkey anti-goat HRP 
secondary antibody (sc-2020, Santa Cruz Biotechnology; Santa Cruz, CA) was diluted 1:2000 
and incubated with the membrane for 1 hour.  They were washed with TBST and developed 
using Amersham
TM
 ECL
TM
 Western Blotting Detection Reagents (GE Healthcare; 
Buckinghamnshire, UK).  The membranes were then stripped and re-exposed to ECL to confirm 
stripping.  Next, they were blocked and reprobed with 4-HNE primary antibody (393207; 
Calbiochem; Merck, Darmstadt, Germany).  After appropriate washing, membranes were 
exposed to goat anti-rabbit IgG HRP for 1 hour (DC03L; Calbiochem), washed and developed as 
previously indicated. 
Analysis of Polyamine Levels.  Polyamines were detected by the use of a fluorescent HPLC 
protocol (Brachet et al., 1996).  Although the assay was designed to detect Put, Spd, and Spm, I 
was only able to reliably detect Spd and Spm levels.  The mouse liver was homogenized in 250 
µl of 0.4 M HClO4 and centrifuged at 1,500 x g for 15 minutes.  The derivatization required 
dansylation of the polyamines for detection by fluorescence.  The reaction mixture consisted of:  
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100 µL supernatant, 400 µL of 10 mg/mL dansyl-Cl, and 200 µL of saturated sodium carbonate.  
The reaction proceeded in the dark for 90 minutes at 50°C.  The reaction was halted with 100 µL 
L-proline (100 g/L) for 30 minutes at 50°C.  Spd and Spm were separated on a Luna 5u C18 250 
x 4.6 mm ID column from Phenomenex.  The program was a linear gradient from 100% solvent 
A: 0% solvent B to 0% solvent A:100% solvent B over a 28 minute period followed by 10 
minutes at 100% solvent B.  The flow rate was 1.5 mL/min.  The excitation wavelength was 338 
nm and the emission wavelength was 425 nm.   
Determination of Mitochondrial Glutathione.  Mitochondrial GSH was determined using a 
spectrophotometric assay (Anderson, 1985).  For the assay, 200 mg of liver was homogenized in 
5% sulfosalicylic acid (SSA) for a final volume of 1 mL.  GSH was assessed using glutathione 
reductase with 5,5’-dithiobis(2-nitrobenzoic acid) and NADPH.  GSSG was measured by 
derivitizing the samples with 2-vinylpyridine first allowing determination of a percentage of 
oxidized glutathione within the cell.   
Post-translational modifications: Samples were run on a 2D SDS-PAGE gel and selected spots 
were isolated. Spots that exhibited increased 4-HNE adduction on the 2D gel in the APAP group 
compared with the S + A group were selected.  Selected spots of interest were analyzed at the 
University of Arizona Proteomics center using a LTQ-Orbitrap Mass Spectrometer (financial 
support provided by National Institute of Health National Center for Research Resources 1 S10 
RR028868-01). The data was analyzed using SEQUEST and Scaffold software.  
Statistical Analysis:  All values are reported as mean ± S.E.M. with n = 5 animals per group.  
The final number of animals for each experiment is noted below in the results section.  
Differences between the groups were determined using a One-Way ANOVA followed by a 
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Tukey’s post-hoc test (SigmaStat; SPSS Inc. Chicago, IL).  Significant differences were assessed 
using  = 0.05.   
Results:   
ALT.  APAP administration significantly elevated plasma ALT at 4 hours (Figure 22).  SAMe 
administration following APAP significantly decreased plasma ALT at the same time period.   
  
 
 
 
 
Figure 22.  Plasma ALT levels in C57Bl/6 mice 4 h after APAP overdose.  Mice were 
randomly allocated into the above listed groups and blood collected by cardiac puncture for ALT 
analysis.  Values represent mean ± S.E.M. with n = 5 mice per group.  Different letters denote 
statistical differences (p<0.05) between the groups.   
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Proteomics.  A 2D gel was run in the Dr. Lau’s laboratory and 10 spots were identified for 
analysis in both the mitochondrial and cytosolic fractions that were positive for 4-HNE binding. 
Figure 23 is an image of the 2D gel with the 10 spots identified. These spots were then analyzed 
for 4-HNE adduction (Table 9) and methionine oxidation (Table 10).  
 
Figure 23. This is a representative 2D gel of mitochondrial samples 4 hour post APAP 
treatment.  The left panel is protein staining and the right panel is 4-HNE adducted proteins.   
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Table 9. 4-HNE Protein modifications 4 hours Post APAP in Mitochondrial and Cytosolic 
proteins 
*The number of peptides represents how many individual peptides were adducted with 4-HNE.  
In cases where a spot is listed, the protein was observed at multiple locations corresponding with 
the spots identified in Figure 23.  In the % coverage column, 4-HNE adduction contributes to the 
percent of global protein modification caused by APAP overdose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein Accession 
number 
MW 
(kDa) 
Subcellular 
location 
Number 
of 
peptides 
% 
Coverage 
Aldehyde 
dehydrogenase, 
mitochondria 
IPI00111218 57  Mitochondria 6-Spot 5 
35-Spot 6 
33-Spot 9 
22-Spot 5 
55-Spot 6 
55-Spot 9 
Carbamoyl 
phosphate 
synthetase 
(CPS-1) 
IPI00111908 164 Mitochondria 49-Spot 3 
35-Spot 6 
34-Spot 8 
36-Spot 3 
30-Spot 6 
29-Spot 8 
Hypoxia up-
regulated protein 
IPI00123342 111 Mitochondria 46 51.25 
Acyl-CoA 
dehydrogenase 
family member 9, 
mitochondria 
IPI00331710 69 Mitochondria 13 26.24 
Protein disulfide 
isomerase 
IPI00133522 57 Mitochondria 50 70.33 
Alanine 
aminotransferase 
IPI00319992 55 Mitochondria 23-Spot 8 
18-Spot 9 
56-Spot 8 
47-Spot 9 
78 kDa glucose-
regulated protein 
IPI00319992 72 Mitochondria 24 38.02 
Plastin-3 IPI00115528 71 Mitochondria 14 23.49 
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Table 10. Methionine S-Oxidation modifications in Mitochondrial and Cytosolic Proteins 4 
hours Post APAP 
Protein Accession 
number 
MW (kDa) Subcellular 
location 
Number 
of 
peptides 
% Average 
Coverage 
Alanine 
aminotransferase 
IPI00154045 55 Mitochondria 15 23 % 
Aldehyde 
dehydrogenase 
IP100111218 57  
Mitochondria 
12 6% 
ATP Synthase 
subunit beta 
IPI00468481 56 Mitochondria 8 8% 
Betaine-
homocysteine S 
methyltransferase 
IPI00130950 45 Mitochondria 3 9% 
Carbamoyl 
phosphate 
synthetase 
(CPS-1) 
IPI00111908 16 Mitochondria 62 4% 
Hypoxia up-
regulated protein 
IPI00123342 11 Mitochondria 12 16% 
Glucose regulated 
protein 78kDa 
IPI00319992 72 Mitochondria 71 11% 
Mitochondrial 
Stress protein 
IPI00880839 73 Mitochondrial 5 11% 
S-
adenosylmethionine 
synthase 
IPI00454016 44 Mitochondria 1 3% 
Sarcosine 
dehydrogenase 
IPI00136213 102 Mitochondria 1 1% 
*The number of peptides represents how many individual peptides were modified with 
methionine S-oxidation.  In the % coverage column, methionine S-oxidation modification 
contributes to the percent of global protein modification caused by APAP overdose. 
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4-HNE Western Blots.  Our previous collaboration with Dr. Serrine Lau from the University of 
Arizona on 4-HNE adduction lead to a possible mitochondrial target of carbamoyl phosphate 
synthase-1 (CPS1).  We decided to confirm their mass spectrophotometry results to see if we 
have a novel target for 4-HNE adduction in cases of APAP overdose.  First, we sought to find if 
CPS-1 leaks from the mitochondria as cytochrome c does following APAP overdose.  CPS-1 
appeared in the cytosol in a significantly higher amount following APAP overdose (Figure 24).  
SAMe given following APAP decreased leaking of CPS-1 into the cytosolic fraction (Figure 24).  
SAMe alone did not alter CPS-1 in either the mitochondria or cytosol.   
 
 
Figure 24.  Mitochondrial and cytosolic fraction CPS-1 expression 4 hours following APAP 
overdose.  Panel A contains the results for the CPS-1 Western blots.  Protein expression was 
normalized to total protein lane staining.  Values represent mean ± S.E.M. with n=3-5 mice per 
group.  Superscripts denote statistical differences between the groups.  Panel B contains 
representative mitochondrial (top) and cytosolic (bottom) CPS-1 Western blots 4 hours following 
APAP administration.  Lanes marked with the appropriate treatment.  Different letters denote 
statistical differences (p<0.05), while groups with the same letters indicate no difference in the 
results. 
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We also demonstrated 4-HNE adduction of CPS-1 confirming Dr. Lau’s previous work.  CPS-1 
in the cytosol immunostained with 4-HNE antibody exhibited greater 4-HNE adduction in the 
APAP group than the S+A group (Figure 25).  Although some CPS-1 leakage was also observed 
when SAMe was given following APAP, the CPS-1 bands were not positive for 4-HNE 
adduction after the blots were stripped and re-probed for 4-HNE.    No significant adduction of 
CPS-1 by 4-HNE was observed in either the Veh or SAMe treatment groups.  
   
Figure 25.  4-HNE adduction of cytosolic CPS-1 4 hours following APAP overdose.  Panel 
A(top) is a representative CPS-1 Western blot 4 hours following APAP administration.  The blot 
was stripped and re-probed with 4-HNE antibody to confirm adduction.  Groups are listed above 
the respective lanes.  Relative protein expression is depicted in Panel B. APAP increased 4-HNE 
adduction of CPS-1. Different letters denote statistical differences (p<0.05), while groups with 
the same letters indicate no difference in the results. 
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Next, we examined mitochondrial and cytosolic fractions for oxidative stress. Figure 26 shows a 
Western analysis for cytosolic 4-HNE adduction 4 hours after APAP treatment. Figure 27 is a 
representative gel for the mitochondrial fraction. APAP increased mitochondrial and cytosolic 4-
HNE adduction relative to VEH, SAMe and S+A groups. The relative amount of mitochondrial 
4-HNE protein adduction at 2 and 4 hours post APAP are shown in Figure 28.  
 
Figure 26.  4-HNE cytosolic protein adduction following APAP toxicity.  Representative 4 
hour Western blot used to examine 4-HNE adduction levels in Figure 28.  
 
 
 
 
 
Figure 27. 4-HNE Adducted Proteins in Mitochondrial Fraction.  Representative 4-HNE blot 
of Veh, SAME, APAP and SAMe treatment 1 hour after APAP (S+A). Mitochondrial samples 
depicted are 4 hours post APAP treatment. Densitometry analysis is shown in Figure 28.  
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Figure 28.  4-HNE adduction of mitochondrial and cytosolic proteins 2 and 4 hours 
following overdose.  Western blot analysis was conducted on mouse liver homogenate 2 and 4 
hours following APAP overdose and 1 and 3 hours following SAMe administration respectively.  
Panel A and B represent cytosol and mitochondria 2 hours following APAP overdose.  Panel C 
and D are the same fractions examined 4 hours following APAP overdose.  The most dramatic 
differences were observed in the 4 hour treatment groups where the cytosolic 139 and 109 kDa 
bands were significantly reduced (p<0.05) when SAMe was given after APAP.  Additionally, in 
the mitochondrial samples 4 hours following APAP administration, SAMe was able to reduce the 
signal on the 45 kDa band back to that of Veh (p<0.05).  Different letters denote statistical 
differences (p<0.05), while groups with the same letters indicate no difference in the results. 
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Cytosolic fractions had a greater 4-HNE adduction of bands at MW 109 and 139 kDa in the 
APAP group compared to the VEH, SAMe and S+A APAP groups at 4 hour post APAP. The 
S+A group had less 4-HNE adduction at the 139 kDa cytosolic band than APAP but SAMe did 
not totally prevent 4-HNE adduction as the band intensity was higher than the VEH and SAMe 
groups. Mitochondria VEH, SAMe, and S+A groups showed a similar amount of 4-HNE 
adduction for the 45, 91 and 128 kDa bands. The APAP group had a higher intensity for 4-HNE 
adduction for the 45 kDa band compared to all other groups at 4 hour post APAP. The 91 kDa 
band was increased in the APAP group relative to the Veh and SAMe groups at 4 hour. The 
identity of the proteins comprising these bands is not known. The results indicate that 4-HNE 
adduction occurs at a higher level in the APAP group and this is prevented by SAMe 
administration (S+A group).  
The Effect of SAMe on Mitochondrial GSH Following APAP overdose.  Our laboratory 
previously demonstrated the ability of SAMe to protect against APAP toxicity induced GSH 
depletion.  We expanded upon that finding by examining at 4 hour mitochondrial GSH levels 
following APAP overdose.  The percentage of oxidized GSH was significantly increased 4 hours 
following APAP administration (Figure 29).  SAMe decreased the amount of oxidized GSH to 
Veh levels.   
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Figure 29.  Mitochondrial percent oxidized GSH 4 hours after APAP administration.  Mice 
were randomly allocated into Veh (water), SAMe (1.25 mmol/kg), APAP (250 mg/kg), and 
SAMe administered 1 hour following APAP.  Livers were collected 4 hours following APAP 
administration and analyzed for total and oxidized glutathione to calculate the percent oxidized 
glutathione.  All values represent mean ± S.E.M. with at least 4 mice represented in each group.  
Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results. 
 
Polyamine Levels Following APAP Toxicity.  SAMe has an integral role in the synthesis of Spd 
and Spm by acting as a propylamine donor in their synthesis.  We therefore examined levels of 
those polyamines with APAP toxicity to determine if SAMe has a role in their synthesis during a 
toxic event.  We also sought to examine Put levels; however, we were never able to reliably 
ascertain a Put peak (data not shown).  At 2 hours following APAP administration, there was no 
difference in either Spd or Spm levels in any group compared with Veh (Table 11).  However, at 
4 hours, APAP treatment significantly increased Spd levels compared with Veh possibly 
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indicating increased flux through the polyamine pathway.  Furthermore, when SAMe was given 
following APAP, the increase in Spd was significantly higher than the APAP group (Table 11).  
SAMe alone had no effect on Spd levels.   
In contrast to Spd, Spm levels were decreased at 4 hours in the APAP treatment group (Table 
11).  SAMe alone had no significant effect on Spm levels even though there was an increase 
compared with Veh.  Additionally, although SAMe increased Spm levels back to where they 
were not different than Veh, this did not represent a significant increase over the APAP only 
group (Table 11).  By 6 hours, levels of Spd had returned to Veh levels in every treatment group 
and there were no significant differences.  Spm, however, was still significantly decreased 6 
hours following APAP administration compared with Veh (Table 11).  Although SAMe was able 
to significantly increase polyamine levels at 6 hours when given following APAP, it did not 
succeed in returning levels to that of Veh mice.  SAMe alone did not alter Spm levels at 6 hours.   
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Table 11.  Polyamine levels following APAP overdose in C57BL/6 mice. 
 
*Mice were randomly allocated into the following groups: Veh (water), SAMe (1.25 mmol/kg), 
APAP (250 mg/kg), SAMe 1 hour after APAP (S + A). SAMe and APAP were administered by 
ip injection. Values represent Mean ± S.E.M. (n=5). Spd and Spm levels were measured  2, 4  or 
6  hour post APAP or Veh. 
 
abc
 Different letters denote statistical differences (p<0.05), while groups with the same letters 
indicate no difference in the results.  
Conclusion   
Mitochondria have been recognized as an early target for APAP overdose. Generation of oxygen 
radicals during APAP overdose can lead to post-translational modifications of proteins by 4-
HNE. Proteins can also be adducted by NAPQI, the toxic metabolite of APAP. The effect of 
these adductions is not known and future studies need to evaluate the long term effects of 
adduction on protein and enzyme function. The results of our study show that 4-HNE adducts 
proteins in the mitochondria and cytosol. SAMe administered 1 hour after APAP reduces APAP 
hepatic toxicity when evaluated 4 hours after APAP overdose. SAMe also prevents 4-HNE 
adduction of proteins in the mitochondria and cytosol. Proteomic analysis indicated 2 
mitochondrial proteins (CPS-1 and sarcosine dehydrogenase) are adducted by 4-HNE. Further 
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studies indicated that CPS-1 leaks from the mitochondria into the cytosol following APAP 
administration and that SAMe reduced this leakage.  
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Chapter VI:  Summary and Conclusion 
At the end of this thesis research, my project is as fascinating to me today as it was when I began 
the study over six years ago.  In the field of toxicology, APAP is without doubt one of the most 
studied chemical entities.  APAP even has an entire section devoted to its toxicity annually at the 
Society of Toxicology meeting.  Additionally, SAMe represents an intriguing treatment option 
for APAP toxicity.  Therefore, the goal of my work was to move SAMe forward as a potential 
therapeutic alternative to treat the high rate of APAP overdose observed in the United States.  
My work provides evidence for the ability of SAMe to protect against major causes of APAP 
toxicity, as well as highlighting the novel features that SAMe possesses over NAC that warrant 
further study and potential consideration of SAMe to treat APAP overdose in humans. 
Cross-translation Between C57Bl/6 Mice and Humans 
Perhaps the most pressing concern with any study using an animal model is the translation to 
humans.  As stated in the methods and materials in Chapter II, the C57Bl/6 mouse model is an 
excellent analog for human metabolism of APAP.  As for SAMe, its use as a drug in both 
humans and animals is also very well characterized.  One of the attractive characteristics of 
SAMe as a potential therapeutic intervention is its oral bioavailability.  Oral SAMe is absorbed 
primarily in the duodenum (Stramentinoli, 1987).  Humans administered enteric coated 
14
C-
SAMe tablets demonstrated elevated plasma levels out to 48 hours following administration.  In 
contrast, IV SAMe levels rapidly decline in human subjects over the same time period.  
Therefore, oral SAMe may actually be the more favorable treatment.  This could prove 
advantageous for two reasons.  First, SAMe would be directly delivered to the liver through 
portal blood system to a person suffering from APAP overdose.  Second, there would not be 
metabolism and deposit of SAMe in other areas of the body such as the cerebrospinal fluid.  
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Approximately 60% of an oral dose in humans was maintained in stable pools (Stramentinoli, 
1987).  However, these experiments were conducted in otherwise healthy humans, not ones 
suffering from toxicity.  There has been one study on oral SAMe in mice with APAP toxicity.  
BALB/c mice were protected by SAMe given orally (Oz et al., 2004).  However, we chose not to 
use oral SAMe due to the prohibitive cost required to feed mice a steady diet of SAMe.  An 
additional shortcoming of oral administration is the imprecise nature of the amount of SAMe 
ingested by the mice due to differences in feeding habits (Oz et al., 2004).  Therefore, 
intraperitoneal injections of SAMe were used prior to my arrival in my thesis advisor’s 
laboratory.  
Further evidence of portal transport of SAMe being critical to absorption in the liver is found in a 
study using isolated perfused rat livers (Zappia et al., 1978).  The researchers found that the 
uptake of SAMe by the liver was around 20% of the administered dose.  However, of the SAMe 
absorbed, only 1% ended up in the bile, indicating the trapping of SAMe within hepatocytes.  
Another interesting finding from this study was decreased SAMe absorption in fatty liver 
induced by a choline deficient diet.  SAMe absorption in the damaged fatty liver was less than 
the healthy liver (Zappia et al., 1978).  This finding is of interest in context of my research.  
Examination of the 2 hour SAMe and S + A groups demonstrates that SAMe given after APAP 
is incorporated into mouse liver at a higher rate than the healthy SAMe only treatment group.  
Although fatty liver and APAP toxicity are different conditions, the difference in absorption is 
interesting.   
All of these findings indicate that SAMe ip injection is a plausible analog for oral SAMe 
administration. Intraperitoneal injections are second only to IV in their rate of absorbance (Gad, 
2007).  Additionally, drugs given intraperitoneal are absorbed through the portal circulation of 
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the animal, which is a valid approximation of an oral dose of SAMe.  Therefore, I believe that 
our model is well suited as an animal model, allowing inference to oral dosing in humans. 
Liver Homogenate SAMe and SAH Levels Following APAP Overdose 
My work clearly demonstrates intraperitoneal absorption of SAMe particularly at the early time 
points.  An interesting additional experiment would be to examine SAMe levels in the plasma to 
determine if the spike observed in the 2 hour group where SAMe was given following APAP 
corresponds with decreased plasma availability of SAMe.  In essence, do we see higher than 
20% absorption of SAMe in cases of APAP toxicity?  
Certainly, an interesting finding was that administration of NAC was able to maintain SAMe 
levels comparable to control at 4 hours following APAP administration.  However, compared 
with the 4 hour SAMe group, the ratio was not significantly different in the group where NAC 
was given after APAP.  The ratio of SAMe:SAH is critical for transmethylation reactions and, 
therefore, this could represent a subtle, but important, difference between SAMe and NAC 
treatment.  One interesting unexplored variable in liver toxicology is what happens to SAH 
levels following APAP overdose.  
Based on research discussed in the literature review, it is clear that elevated SAH levels inhibit 
critical cellular transmethylation reactions that could prove detrimental to hepatocytes.  
Therefore, an interesting question is the disposition of SAH in response to APAP toxicity.  One 
possible answer is flux through the transsulfuration pathway to synthesize cysteine leading to 
enhanced GSH synthesis in the manner discussed earlier.  Prudova et al. (2006) determined that 
cystathionine -synthase, the enzyme responsible for converting homocysteine to cystathionine, 
was stabilized by the presence of SAMe.  At the earliest time point studied, 2 hours, we noted a 
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significant increase in the ratio of SAMe:SAH (Figure 6).  Examination of this data indicates that 
SAMe is not significantly decreased at that time point, but SAH is significantly depressed by 2 
hours.   
SAMe is a finite commodity within the cell.  Therefore, once SAMe levels are depleted by 4 and 
6 hours, it is unable to stabilize cystathionine -synthase allowing accumulation of extra SAH 
decreasing the ratio of SAMe:SAH.  However, this is a largely academic argument as there is 
clear evidence of GSH depletion within 15 minutes of APAP administration (Knight et al., 
2001).  Administration of SAMe following APAP not only provides substrate for additional 
GSH, but prior research from our laboratory demonstrates significant increases in GSH when 
SAMe is given as an antidote to APAP administration (Terneus et al., 2008).  Thus, even though 
SAH levels increase in the S + A groups at 4 and 6 hours (Figure 6), there is a plausible outlet for 
the extra SAH generated due to the observed increase in SAMe at the same time period.  Indeed, 
examining the N + A group in comparison to the S + A group at 4 hours (Tables 4 and 5), one 
finds that SAMe did lower SAH levels compared with Veh when given after APAP, albeit not 
significantly.  However, NAC under the same conditions had slightly higher SAH levels when 
given as an antidote.  An interesting future study would be to examine cystathionine -synthase 
following APAP toxicity and determine the effect of SAMe on its expression and activity when 
given as an antidote to APAP overdose.   
There is little evidence for the recycling of homocysteine to SAMe through the methionine cycle.  
A review of the literature yields no information on the important cofactor Vitamin B12 during 
APAP toxicity.  This vitamin is necessary for the function of methylfolate-homocysteine 
methyltransferase (Finkelstein, 1990).  Folate, which is also essential in homocysteine recycling, 
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appears unaffected by long-term administration of APAP (Varela-Moreiras et al., 1994).  
Recycling of SAH to SAMe seems unlikely; it would be far easier for a cell to simply use the 
SAH to replenish the rapidly diminishing stores of GSH. 
Mitochondrial and Nuclear SAMe Following APAP Overdose 
The overwhelming majority of work on SAMe and mitochondrial function in instances of 
toxicity has focused on ethanol toxicity in hepatocytes.  In those studies, there is convincing 
evidence that SAMe can protect mitochondrial protein synthesis (Sykora et al., 2009) and also 
protects against oxidative stress damage to the oxidative phosphorylation pathway by stimulating 
synthesis of protective proteins (Andringa et al., 2010).  Certainly, protection against oxidative 
stress induced mitochondrial damage is an attractive prospect.  Additionally, Song and others 
(2007) used 3-deza-adenosine to inhibit S-adenosylhomocysteine hydrolase that is responsible 
for breaking down SAH into homocysteine and adenosine.  Inhibition of this critical methionine 
cycle enzyme lead to greatly reduced mitochondrial.  We demonstrated that giving SAMe after 
APAP overdose protects mitochondrial SAMe levels that are key to mitochondrial function 
(Figure 8).  As will be discussed later, this retention of SAMe also protects mitochondrial GSH 
levels.   
APAP decreased SAMe levels below detection.  There is sparse information relating to nuclear 
SAMe levels in instances of toxicity.  SAMe was able to prevent nuclear blebbing in arsenic 
treated lymphocytes (Ramirez et al., 2003).  Whether this is at all applicable to the current 
research is unknown.  However, there is the potential for an interesting follow-up study looking 
at the effect of APAP, a short-term toxicant, on long-term DNA methylation levels following 
overdose.  A bacterial study demonstrates that APAP does adduct DNA, most likely through 
NAPQI (Dybing et al., 1984).  It is interesting to speculate about the consequences of APAP 
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adduction to DNA in survivors of APAP overdose.  Of particular concern is the liver since it has 
significant regeneration following APAP overdose in survivors.   
Methionine Adenosyltransferase 
We decided to examine MAT expression and activity in order to ascertain whether it might play 
a role in SAMe depletion following APAP overdose.  APAP has been demonstrated to reduce 
MAT activity in mice (Shirota et al., 2002).  However, we did not find changes in MAT activity 
at either 2 or 4 hours post APAP administration.  This represents one of the more vexing findings 
in the research, but I have a few theories to explain these results.  First, we used 250 mg/kg 
APAP and the study showing inhibition used 400 mg/kg APAP.  Second, we did not see any 
expression of MAT II which would be anticipated to be induced when SAMe is given after 
APAP.  I suggest that longer term studies may prove beneficial in determining MAT II activity if 
present.  Despite these vexing findings, we demonstrated for the first time that expression of 
MAT I/III is decreased both 2 and 4 hours after APAP overdose and that SAMe protects MAT 
expression (Figure 11).   
Improvement in Antioxidant Enzyme Function by SAMe 
Our work found improvement in all liver homogenate antioxidant enzyme function in the S + A 
group at the 4 hour time point (Figures 13-17).  We are proposing SAMe as an alternative 
treatment to NAC for APAP toxicity and a key question is how the two treatments compare in 
regards to antioxidant enzyme function.  In a perfect world, we would have had time to conduct 
the NAC studies in our model for a valid comparison; however, that is one of a few experiments 
left to be done by a future graduate student. 
- 139 - 
 
Several studies have also looked at NAC protection of antioxidant enzyme function with APAP 
overdose.  One study looked at NAC given 30 minutes before a 400 mg/kg APAP dose.  Livers 
were collected at 6 hours.  GSSG reductase was increased, but not back to levels of control 
animals in the study (Acharya and Lau-Cam, 2010).  SAMe, by comparison, returned GSSG 
reductase to a level similar to Veh by 4 hours indicating, in this case, SAMe provides better 
protection than NAC which by 6 hours had not yet returned GSSG reductase activity to control 
levels.  Another study in Wistar rats given NAC daily for 15 days prior to APAP injection (650 
mg/kg) found that catalase, SOD (unspecified), and GPx were returned to control levels by NAC 
(Yousef et al., 2010).  However, this is not a clinically relevant way to administer NAC to 
counteract APAP overdose. 
The question remains whether NAC and SAMe are equivalent in preserving antioxidant enzyme 
function subsequent to APAP overdose.  I do not believe that the two mechanisms of action are 
necessarily mutually exclusive since there is evidence by our laboratory that SAMe replenishes 
GSH levels similar to NAC (Terneus et al., 2008).  Additionally, there is not a good comparison 
study looking at NAC and Mn-SOD, the mitochondrial variant of SOD.  Yoshikawa and others 
found that knockdown of Mn-SOD greatly increases hepatotoxicity secondary to APAP overdose 
in rats (Yoshikawa et al., 2009).  The major source of oxidative stress in APAP toxicity revolves 
around the mitochondria and, therefore, damage to Mn-SOD would be expected to worsen 
toxicity.  By 4 hours, there is a clear depression of Mn-SOD activity in the APAP treatment 
group.  SAMe partially corrects this decrease which could prove very advantageous to the cell.  
Whether this effect of SAMe on Mn-SOD is due to a unique action of SAMe, or a byproduct of 
GSH replenishment, remains to be determined.  In summary, both SAMe and NAC seem to 
provide critical antioxidant enzyme protection following APAP overdose.   
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Mitochondrial Protection by SAMe 
To my knowledge, our laboratory was the first to examine mitochondrial protein carbonyl 
formation associated with APAP toxicity.  There are parallels in other mitochondrial toxicants, 
however.  For instance, lipoic acid can reduce protein carbonyl formation on mitochondrial 
proteins brought about by methotrexate (Tabassum et al., 2010).  Additionally, we found at both 
2 and 4 hours, protection in the treatment S + A treatment groups (Figure 18).   
Similarly, 3-NT formation on mitochondrial proteins has been investigated using a scavenger of 
peroxynitrite (Loguidice and Boelsterli, 2011).  The authors found that scavenging with a 
peroxynitrite specific scavenger prevents mitochondrial 3-NT protein formation.  This was 
obviously not the focus of their work, but a byproduct of the data collected.  Our work shows for 
the first time that a non-peroxynitrite treatment for APAP overdose is able to prevent 3-NT 
mitochondrial protein formation.  Further confirmation of the reduced oxidative stress is noted 
by our findings that oxidized glutathione is maintained at normal levels when SAMe is given 
after APAP (Figure 29).  Additionally, we discovered that SAMe prevents leakage of proteins 
known to increase in concentration in the cytoplasm following APAP overdose.   
The literature lays out a clear case for cytochrome c leakage from the mitochondria during APAP 
toxicity.  There is also evidence that treatment of APAP overdose can prevent cytochrome c 
release from the mitochondria (Latchoumycandane et al., 2006).  NAC has been examined 
preventing the mitochondrial swelling with APAP toxicity, but not cytochrome c release.  
Additionally, SAMe protects against ethanol induced mitochondrial cytochrome c release in the 
liver, but had not previously been examined with APAP toxicity (Cabrales-Romero Mdel et al., 
2006).   
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A 2002 study found that cytochrome c release is governed by two factors.  First, mitochondria 
become electrodestabilized (Ott et al., 2002).  The authors argue that lipid peroxidation could be 
a cause of this destabilization.  Second, the cytosolic protein Bax must translocate to the 
mitochondria to allow release of the newly freed cytochrome c.  A recent study by Kumari and 
Kakkar demonstrates that preventing Bax translocation to the mitochondria decreases 
cytochrome c release due to APAP toxicity (Kumari and Kakkar, 2012).  The literature on SAMe 
and Bax mainly focuses on the paradoxical ability of SAMe to induce apoptosis in cancer cell 
lines (Zhao et al., 2002).  In the PC12 cell lines, SAMe increases Bax levels thereby facilitating 
apoptosis.  However, the role of SAMe in cancer treatment is beyond the scope of the current 
work.  What we can infer is that SAMe decreases mitochondrial dysfunction and, theoretically, 
Bax translocation to the mitochondria, thereby creating the observed decrease in cytochrome c 
leakage into the cytosol.  Future studies should investigate Bax translocation in our APAP 
toxicity model to further elucidate the role of SAMe in Bax translocation.   
Finally, we assessed mitochondrial swelling to determine whether SAMe reduced this sequelae 
of APAP toxicity.  At 2 and 4 hours SAMe did not prevent mitochondrial swelling when given 
after APAP (Figure 20).  Thus, SAMe does not prevent all the mitochondrial effects of APAP 
toxicity.  As discussed earlier, there is depletion of GSH within 15 minutes of APAP 
administration and we did not give SAMe for a full hour after APAP. Therefore, significant 
mitochondrial damage may already have occurred.  We also used a harsh swelling assay that 
might have ensured swelling even in mitochondria partially protected by SAMe.   
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Polyamine Metabolism Following APAP Overdose, A New Perspective on SAMe Treatment of 
Toxicity 
Previous attempts at preventing toxicity by increasing polyamine levels focused largely on 
injecting Put to boost levels of both Spd and Spm (Daikuhara et al., 1979).  SAMe represents a 
promising therapeutic alternative to Put due to its well characterized human pharmacokinetics.  
Additionally, SAMDC and ODC have been examined during liver regeneration.  Activity of both 
SAMDC and ODC is increased following a partial hepatectomy in rats (Pegg et al., 1982).  
However, the distinction between a partial hepatectomy and active fulminant liver necrosis must 
be noted.  Given the role of components of the polyamine pathway at not only protecting the 
liver, but also aiding in liver regeneration, it is surprising that no one had examined SAMe as a 
potential therapeutic intervention aimed at increasing polyamine levels.   
We attempted to examine levels of ODC and SAMDC via Western blot (data not shown).  
However, the results were unsuccessful and future studies will need to examine not only their 
expression, but also their function.  In contrast, we were able to produce an intriguing time 
course study on Spd and Spm levels.  Unfortunately, low levels of Put, coupled with background 
noise in the HPLC histogram, prevented us from determining the levels of Put.  Since SAMe 
would not enter at the level of Put, but rather, dcSAMe would enter polyamine synthesis at Spd 
and Spm, our inability to measure Put does not detract from our findings  Spd is increased in 
both the APAP and S + A groups in the 4 hour treated mice.  The fact that the S + A group had 
significantly increased Spd compared with the APAP minus SAMe group also indicates that 
exogenous SAMe cycles through the polyamine synthesis pathway following APAP overdose.  
Since Spd is required for growth and differentiation of cells this increase in Spd could be linked 
to subsequent liver regeneration.   
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The effect of APAP and SAMe on polyamines needs further investigation.  Long-term 
measurements of liver regeneration could potentially distinguish between the effectiveness of 
SAMe vs. NAC as a therapeutic intervention for APAP toxicity.  If SAMe enhances liver 
regeneration, then its therapeutic potential could expand to a myriad of liver toxicants.  Any 
potential therapy that could induce regeneration of the liver and reduce the need for liver 
transplants would be very beneficial.   
Conformation of a Mitochondrial 4-HNE Adducted Protein CPS-1 
My thesis work focused heavily on mitochondrial function protection by SAMe when used as an 
antidote to APAP toxicity.  Previous work on the subject by Dr. Marcus Terneus demonstrated 
SAMe protection against liver homogenate 4-HNE protein adduction (Terneus et al., 2008).  This 
work has been part of an ongoing collaboration with Dr. Serrine Lau at the University of Arizona 
in an attempt to examine specific proteins adducted with 4-HNE following APAP toxicity.  In 
2005, Dr. Lau’s laboratory determined protein targets of 4-HNE (data not shown).  Adduction by 
the lipid peroxidation byproduct 4-HNE could increase APAP toxicity and represents a new and 
heretofore unexamined pathway of APAP toxicity.  Therefore, we sought to examine one of the 
earlier targets identified by Dr. Lau to confirm adduction, CPS-1.  Additionally, we examined 
global mitochondrial 4-HNE adduction and the ability of SAMe to prevent the adduction.   
4-HNE adducts the mitochondrial protein SIRT3 and inhibit its activity (Jacobs and Marnett, 
2010).  Therefore, modification by 4-HNE adduction could play a critical role in toxicity.  We 
were able to successfully confirm with Western blotting the earlier work of Dr. Lau’s laboratory 
that CPS-1 was adducted by 4-HNE.  While perhaps not directly implicated in cellular death 
following APAP toxicity, CPS-1 dysfunction could increase ammonia concentrations in the 
blood of recovering patients.  Additionally, our findings support prior work that APAP toxicity 
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significantly reduces CPS-1 activity (Gupta et al., 1997).  There is evidence in rats that this 
increase in ammonia disrupts the blood brain barrier in rats (Scorticati et al., 2004).  It is likely 
that the buildup of ammonia is predominantly a result of the observed necrosis of the liver 
disrupting the urea cycle, with CPS-1 modification playing a minor role.  In addition to 
adducting proteins, 4-HNE is detoxified in part by GSH further depleting stores in the 
hepatocytes and increasing toxicity (Fritz and Petersen, 2011).  Furthermore, SAMe clearly 
reduces mitochondrial 4-HNE adduction of CPS-1 and other proteins.  These effects would prove 
advantageous to the survival of the cell by helping maintain proper energy gradients within the 
hepatocytes.  Additionally, SAMe prevents both 4-HNE adduction and oxidative damage 
following APAP overdose.  This is a novel finding involving SAMe effects on APAP toxicity 
and warrants further study. 
In Conclusion 
My thesis research over the past six years has led to a better explanation of the mechanism by 
which SAMe is able to prevent APAP toxicity (Figure 30).  While a mechanistic understanding 
is not essential for use as a therapeutic intervention, one wonders if APAP would have been able 
to obtain FDA approval today if it was unknown how it worked.  Additionally, work in Italy in 
the past decade has found use for SAMe in a medical prevention of liver toxicity.  Researchers 
found patients being treated for cancer were able to extend treatment windows with reduced 
hepatotoxicity when SAMe was used as adjuvant therapy (Santini et al., 2003).  I firmly believe 
that SAMe has great potential not only for APAP toxicity treatment, but a host of other liver 
toxicity disorders.  Best of all, it is a natural product that our bodies produce large quantities of 
every day.  I am excited to see what the future holds for SAMe as a therapeutic intervention. 
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Figure 30.  Summary of SAMe protection against APAP toxicity.  I propose that exogenously 
administered SAMe protects against APAP toxicity by preventing antioxidant enzyme 
dysfunction.  Protection of the antioxidant enzymes prevents formation of ROS and RNS and 
subsequent adduction by 4-HNE and formation of 3-NT on mitochondrial proteins.  Exogenous 
SAMe is also able to maintain SAMe levels inside the cell which enables SAMe to participate in 
both GSH synthesis and Spd and Spm synthesis.  GSH, Spd, and Spm are all protective to the 
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cell.  Spm may possess direct mitochondrial protective ability itself.  My findings offer greater 
understanding on how SAMe is able to so effectively prevent APAP toxicity when given 
following APAP overdose. 
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